Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 100
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer's Disease

  • Fortea, Juan|||0000-0002-1340-638X
  • García-Arcelay, Elena
  • Terrancle, Ángeles
  • Gálvez, Blanca
  • Díez-Carreras, Verónica
  • Rebollo, Pablo|||0000-0002-7517-6540
  • Maurino, Jorge|||0000-0001-9858-3555
  • García-Ribas, Guillermo
Alzheimer's disease (AD) biomarkers reflect key elements of pathophysiology and improve the diagnostic process. However, their use in routine clinical practice is still limited. We aimed to assess neurologists' barriers and enablers to early AD diagnosis using core AD biomarkers. We conducted an online study in collaboration with the Spanish Society of Neurology. Neurologists answered a survey exploring their attitudes towards AD diagnosis using biomarkers in mild cognitive impairment (MCI) or mild AD dementia. Multivariate logistic regression analyses were conducted to determine the association between neurologists' characteristics and diagnostic attitudes. We included 188 neurologists with a mean age (SD) of 40.6 (11.3) years, 52.7% male. Most participants had access to AD biomarkers, mainly in cerebrospinal fluid (CSF) (89.9%,#x0025;, n = 169). The majority of participants (95.2%,#x0025;, n = 179) considered CSF biomarkers useful for an etiological diagnosis in MCI. However, 85.6% of respondents (n = 161) used them in less than 60% of their MCI patients in routine clinical practice. Facilitating patients and their families to plan for the future was the most frequent enabler for the use of biomarkers. Short consultation time and practicalities associated with the programming of a lumbar puncture were the most common barriers. A younger neurologist age (p = 0.010) and a higher number of patients managed weekly (p = 0.036) were positively associated with the use of biomarkers. Most neurologists had a favorable attitude to the use of biomarkers, especially in MCI patients. Improvements in resources and consultation time may increase their use in routine clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

  • Donadeu, Laura|||0000-0002-5089-5047
  • Gómez-Ollés, Susana|||0000-0002-8935-7641
  • Casanova, Franc|||0000-0001-7427-1987
  • Torija, Alba
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Boada Pérez, Meritxell|||0000-0002-8774-8593
  • Kervella, Delphine|||0000-0001-8069-6105
  • Crespo, Elena
  • Carrera-Muñoz, Claudia
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Quintero, Jesús|||0000-0002-6456-9031
  • Muñoz, Marina
  • Agüero, Fernando
  • González-Costello, José|||0000-0002-7437-3630
  • Lladó, Laura|||0000-0002-3717-3306
  • Favà, Alexandre|||0000-0003-1664-6001
  • Cañas, Laura
  • de la Hoz-Caballero, María del Mar
  • Meneghini, Maria|||0000-0001-7307-923X
  • Torres, Irina B.|||0000-0003-3304-0810
  • Juvé, Mariona|||0000-0001-8431-3757
  • Hafkamp, Florianne
  • Vila, Marta|||0000-0001-9303-5189
  • González Robles, Alba
  • Buzón, Maria José|||0000-0003-4427-9413
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Zúñiga, José Miguel
  • Monforte, Víctor|||0000-0002-2918-7679
  • Sáez-Giménez, Berta|||0000-0002-9307-728X
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Pardo, Emma|||0000-0001-8703-5457
  • Martínez, Xavier
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

  • Bolsewig, K.
  • Willemse, E.A.J.
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Rábano, Alberto|||0000-0001-9320-6566
  • Martínez, Minerva|||0000-0002-9036-2595
  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Koel-Simmelink, M.
  • Hussainali, Z.
  • Ruiters, D.N.
  • Gaetani, L.
  • Toja, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.W.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Hort, J.
  • Otto, M.|||0000-0003-4273-4267
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Teunissen, C.E.
  • Campo Milán, Marta del|||0000-0003-2808-3699
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Busto, G.
  • Gabelle, A.
  • Ayrignac, X.
  • Bennys, K.
  • Muiño, Elena|||0000-0001-5839-7328
  • Villatoro-González, Paula|||0009-0001-0287-4073
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pradeilles, N.
  • Bounasri, Shaima El
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Hirtz, C.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Lehmann, Sylvain|||0000-0001-6117-562X
Background: Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to dementia after AD, could also significantly benefit from this advancement. However, no informative fluid biomarker has been identified for VaD. Given the disruption of iron homeostasis in both AD and VaD, this study aims to characterize the potential of the iron-related hormone Hepcidin as a biomarker for these two conditions. We will compare its added value to established AT(N) blood biomarkers. Methods: Blood biomarkers (amyloid-composite, p-Tau, Neurofilament Light Chain [NfL] and Hepcidin) levels in blood were analyzed in two independent cohorts and compared between AD patients and non-AD individuals. Additionally, blood Hepcidin and NfL were evaluated in the contexts of VaD and CADASIL, with their relative diagnostic value assessed. Results: Blood Hepcidin and NfL do not significantly increase the AUC obtained with both p-Tau and amyloid composite in the context of AD. In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone. Hepcidin was not significantly modified in CADASIL patients compared to control subjects. Conclusion: Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and implementation of clinical trials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Potential of facial biomarkers for Alzheimer's disease and obstructive sleep apnea in Down syndrome and general population

  • Echeverry-Quiceno, L.M.|||0000-0002-9799-0252
  • Llambrich, S.|||0000-0001-9980-0208
  • Heredia-Lidón, None|||0000-0001-6325-8744
  • Giménez, Sandra|||0000-0001-8031-2319
  • Aranha, Mateus|||0000-0001-9594-292X
  • Inampudi, P.
  • Heuzé, Y.|||0000-0002-0660-9613
  • Sevillano, X.|||0000-0002-6209-3033
  • Fortea, Juan|||0000-0002-1340-638X
  • Martínez-Abadías, N.|||0000-0003-3061-2123
Down syndrome (DS), caused by trisomy 21, is associated with an increased risk of Alzheimer's disease (AD) and obstructive sleep apnea (OSA). Traditional diagnostic methods for AD and OSA, like cerebrospinal fluid analysis and polysomnography, are invasive and challenging for people with DS. In this study, we assessed whether facial morphology could be used as a potential noninvasive biomarker for these conditions in both DS and the general population. We performed a comprehensive 3D analysis of facial shape variation by registering the 3D coordinates of 21 landmarks on facial models extracted from magnetic resonance images of 131 individuals with DS and 216 euploid (EU) adult controls, including AD and OSA cases. Procrustes ANOVA and MANOVA quantified shape variation by sex, age, and facial size, while geometric morphometrics assessed diagnostic group differences. Significant facial shape differences were observed between the DS and EU groups, indicating sex-dependent differences and altered age-related changes in DS, particularly in females. Facial shape correlated with the amyloid beta ratio (Aβ1-42/Aβ1-40), a key AD biomarker. In DS, facial shape differences by AD diagnosis were not significant after adjusting for age and facial size, but significant shape differences were detected in the EU population. For OSA, facial shape correlated with the apnea-hypopnea index (AHI), and DS individuals with severe OSA showed distinct facial morphology compared with those without OSA, suggesting an association between facial shape and sleep respiratory disturbances. These results highlight the potential of facial morphology as a noninvasive biomarker for AD and OSA detection and management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sleep-related changes in astrocytic biomarkers are modulated by APOE ε4 genotype in cognitively unimpaired adults

  • Zhu, Nuole|||0000-0002-0015-9455
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Carreras-Vega, Mireia
  • Romero, Sergio
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Giménez, Sandra|||0000-0001-8031-2319
  • Alcolea, Daniel|||0000-0002-3819-3245
Astrocytes are key regulators of sleep and neuroinflammatory responses. However, the relationship between objective sleep parameters and astrocytic fluid biomarkers in cognitively unimpaired individuals remains unclear. We examined how sleep architecture relates to astrocytic, neuroaxonal and Alzheimer's disease-related fluid biomarkers in cognitively unimpaired adults, and whether age, sex and APOE ε4 moderate these associations. This cross-sectional study included 51 cognitively unimpaired participants from the Sant Pau Initiative on Neurodegeneration cohort. One-night in-lab polysomnography was used to quantify sleep architecture, fragmentation, slow-wave activity, and respiratory parameters. CSF biomarkers included glial fibrillary acidic protein (GFAP), chitinase-like-3 protein 1 (YKL-40), Aβ42, Aβ40, pTau181, and tTau; plasma biomarkers included GFAP and neurofilament light chain (NfL). Associations were analyzed using Spearman correlations, multiple linear regression, and moderation models, adjusting for age, sex, body mass index, APOE ε4 status, and sleep apnea. Lighter and more fragmented sleep, characterized by longer N1 duration, increased wake after sleep onset, frequent stage transitions, and elevated cortical arousal, was associated with higher CSF YKL-40, Aβ40, pTau181 and tTau (rho = 0.32 to 0.62, all p<0.05). In contrast, deeper, more consolidated sleep, indicated by longer total time of sleep, greater N3 duration, and higher slow-wave activity, was associated with lower CSF GFAP and YKL-40 (rho = -0.35 to -0.44, all p<0.05). These associations remained significant in adjusted regression models. Plasma GFAP and NfL exhibited an inverse profile, with positive associations with deeper sleep (β: 0.16 to 0.18, p < 0.05) and negative associations with lighter sleep stages (β: -0.23 to -0.29, p < 0.01). REM sleep was also associated with astrocytic fluid biomarkers, with negative correlations for CSF and plasma GFAP (rho = -0.49 and rho = -0.28, respectively, all p<0.05), while in regression models REM duration remained a negative predictor of plasma GFAP (β = -0.23, p = 0.003) and a positive predictor of CSF YKL-40 (β = 0.12, p = 0.037). Notably, APOE ε4 consistently moderated associations between sleep and CSF YKL-40 and GFAP, while age and sex influenced plasma GFAP and CSF YKL-40, respectively (all p<0.05). In cognitively unimpaired adults, sleep architecture is differentially associated with central and peripheral biomarkers of astrocytic activation, neuroaxonal integrity and Alzheimer's disease-related proteins. These findings support the importance of considering sleep as a key factor in the early pathophysiology of neurodegenerative disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of amyloid-negative neuropsychological norms using GAMLSS

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Estanga, Ainara|||0000-0002-6616-314X
  • Ecay-Torres, Mirian|||0000-0001-7170-6180
  • de Luis, C.L.
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Castellví, Magdalena|||0000-0001-8769-9288
  • Pozueta, A.
  • García-Martínez, M.
  • Gómez-Andrés, David|||0000-0001-5654-7791
  • Lage, Carmen|||0000-0003-1703-121X
  • López-Garcia, Sara
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Balasa, Mircea|||0000-0002-1795-4228
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Tainta, Mikel|||0000-0003-0624-1211
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
INTRODUCTION: Recent research has suggested increased sensitivity of Alzheimer's disease (AD)-negative neuropsychological norms; concurrently, generalized additive models for location, scale, and shape (GAMLSS) have emerged as a promising alternative to traditional norming approaches. Here, we developed amyloid β-negative (Aβ-) next-generation norms (NGN) for a comprehensive neuropsychological battery using GAMLSS. METHODS: We included N = 987 cognitively normal (CN) individuals from a Spanish multicenter study with extensive neuropsychological data and cerebrospinal fluid AD biomarker assessment. NGN were developed using GAMLSS based on the performance of n = 774 Aβ- CN individuals aged 30-90 years. RESULTS: Age-, education-, and sex-adjusted z-scores were obtained for 14 measures covering the main cognitive domains (memory, language, attention/executive, and visuospatial functions). A user-friendly calculator for the z-scores was made available in an open-access ShinyApp to facilitate their application. DISCUSSION: NGN may improve the detection of objective cognitive impairment in clinical and research settings. Highlights: Brain amyloid β (Aβ) is associated with poorer performance in cognitively normal individuals. We provide GAMLSS-based Aβ-negative norms for 14 neuropsychological measures. Age, education, and often sex significantly influence cognitive performance. An online calculator for the demographically adjusted z-scores is freely available.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. Methods: We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A +) or negative (A-) according to CSF Aβ1-42/Aβ1-40 ratio. Plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ1-42/Aβ1-40 ratio. We analyzed the concordance of pTau217 with CSF amyloidosis. Results: Plasma pTau217 and pTau181 concentration were higher in A + than A- while the plasma Aβ1-42/Aβ1-40 ratio was lower in A + compared to A-. pTau181 and the Aβ1-42/Aβ1-40 ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau217, and 0.88 (95% CI 0.84-0.92) for both pTau181 and Aβ1-42/Aβ1-40. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau217 had the highest fold change (× 3.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau217 using a two-threshold approach was robust in symptomatic groups, exceeding 90%. Conclusion: The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau217 showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Aranha, Mateus|||0000-0001-9594-292X
  • Aragón, Irina
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, S.
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Hernandez, Aida S.
Background and Objectives Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. Methods This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. Results We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEe4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. Discussion In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure, A Propensity Score-Matching Analysis Based on the EAHFE Registry

  • Miró, Oscar|||0000-0002-7924-9751
  • Gil, Víctor
  • Martín-Sánchez, Francisco Javier|||0000-0002-5970-725X
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
  • Jacob, Javier|||0000-0003-1101-1066
  • Mebazaa, Alexandre|||0000-0001-8715-7753
  • Harjola, Veli-Pekka
  • Ríos, José|||0000-0002-0716-8784
  • Hollander, Judd E.
  • Peacock, W. Frank
  • Llorens Soriano, Pere|||0000-0002-9291-7179
Objective The objective was to determine the relationship between short-term mortality and intravenous morphine use in ED patients who received a diagnosis of acute heart failure (AHF). Methods Consecutive patients with AHF presenting to 34 Spanish EDs from 2011 to 2014 were eligible for inclusion. The subjects were divided into those with (M) or without IV morphine treatment (WOM) groups during ED stay. The primary outcome was 30-day all-cause mortality, and secondary outcomes were mortality at different intermediate time points, in-hospital mortality, and length of hospital stay. We generated a propensity score to match the M and WOM groups that were 1:1 according to 46 different epidemiological, baseline, clinical, and therapeutic factors. We investigated independent risk factors for 30-day mortality in patients receiving morphine. Results We included 6,516 patients (mean age, 81 [SD, 10] years; 56% women): 416 (6.4%) in the M and 6,100 (93.6%) in the WOM group. Overall, 635 (9.7%; M, 26.7%; WOM, 8.6%) died by day 30. After propensity score matching, 275 paired patients constituted each group. Patients receiving morphine had a higher 30-day mortality (55 [20.0%] vs 35 [12.7%] deaths; hazard ratio, 1.66; 95% CI, 1.09-2.54; P =.017). In patients receiving morphine, death was directly related to glycemia (P =.013) and inversely related to the baseline Barthel index and systolic BP (P =.021) at ED arrival (P =.021). Mortality was increased at every intermediate time point, although the greatest risk was at the shortest time (at 3 days: 22 [8.0%] vs 7 [2.5%] deaths; OR, 3.33; 95% CI, 1.40-7.93; P =.014). In-hospital mortality did not increase (39 [14.2%] vs 26 [9.1%] deaths; OR, 1.65; 95% CI, 0.97-2.82; P =.083) and LOS did not differ between groups (median [interquartile range] in M, 8 [7]; WOM, 8 [6]; P =.79). Conclusions This propensity score-matched analysis suggests that the use of IV morphine in AHF could be associated with increased 30-day mortality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients

  • Hok-A-Hin, Yanaika S.|||0000-0001-9713-116X
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Barkhof, Frederik|||0000-0003-3543-3706
  • del Campo, Marta
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Vermunt, Lisa
  • Oosthoek, Marlies
  • Vijverberg, Everard G.B.
  • Blujdea, Elena R.
  • Veld, Sjors G.J.G.In't
  • Pucheu Avilés, Martín
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Visser, Allerdien
  • Schut, Martijn C.
Background: Amyloid-related imaging abnormalities (ARIA) are a common and potentially dangerous side effect in anti-amyloid therapies, creating a need for tools to assess ARIA risk. Several patient factors have been linked to ARIA; namely the presence of microbleeds (MBL), APOE E4 carriership (APOE4), and extremely low CSF Aβ42 concentrations (A). We hypothesize that studying the CSF proteome of Alzheimer's disease (AD) dementia patients from a high-risk group (MBLAPOE4A) can inform on the biological underpinnings of ARIA risk and aid the progress of ARIA risk biomarkers. Methods: We utilized CSF proteomic data of AD (n = 156) and cognitively unimpaired individuals (CU n = 100) of the Amsterdam Dementia Cohort. The proteome of the defined high-risk (n = 13) was compared to low-risk AD group (n = 23), using age and sex corrected linear regressions followed by gene ontology analysis. For biomarker prioritization, we selected proteins that were abnormal in the high-risk group versus low-risk and CU patients. The biomarkers were validated in an independent cohort (high risk n = 14, low risk n = 9) analyzed using customized multiplex panels. Lastly, we assessed biomarker lead co-expression. Results: Ninety-four proteins differentiated in the high-risk group compared to low-risk (p < 0.05), none surviving FDR correction. These proteins were enriched for synapse-related proteins and axonogenesis. CHIT1 (vs. low-risk AD: FC = 1.0, p = 0.014, vs. CU: FC = 2.4, p < 0.001) and DDAH1 (vs. low-risk AD: FC=-0.31, p = 0.046, vs. CU: FC = 0.5, p < 0.001) were prioritized as biomarker. DDAH1 protein changes replicated in an independent cohort (FC=-0.37, p = 0.010), and CHIT1 replicated on a trend level (FC = 0.70, p = 0.104). DDAH1 levels had the highest co-expression with synaptic process, energy utilization and RNA-binding cell signaling related proteins (R > 0.8). Conclusions: The findings suggest that in the high risk group, there is a lack of upregulation in synapse and axonogenesis related proteins. High CSF CHIT1 and less increased CSF DDAH1 levels within AD relate to ARIA risk. From the literature, the link to ARIA risk for CHIT1 could be its contribution to innate immunity or vascular amyloid deposition, and for DDAH1 to blood-brain barrier integrity. Biomarker assays are available to assess the potential of CHIT1 and DDAH1 in trials and treatment studies in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Timing of previous heart failure hospitalization as a prognostic factor for emergency department heart failure patients

  • Romero, Carlos|||0009-0002-1803-6303
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Herrera, Sergio|||0000-0001-6134-0402
  • Llorens, Pere
  • Gil, Víctor
  • Curtelin, David
  • Jacob, Javier|||0000-0003-1101-1066
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
  • María Pilar Lopez Díez
  • Llauger, Lluis
  • Luisa López Grima, M.
  • Gil, Cristina
  • Tost, Josep|||0000-0003-3846-9616
  • Agüera Urbano, Carmen
  • Espinosa, Begoña
  • Campos-Meneses, Maria
  • Fernandez, G
  • Torres, A.
  • Escoda, Rosa
  • Martín, Enrique
  • Garrido, Jose Manuel
  • Lucas-Imbernon, Francisco Javier
  • Rodríguez-Adrada, Esther
  • Torres Gárate, Raquel|||0000-0002-8731-9350
  • Andueza, Juan Antonio
  • Peacock, W. Frank
  • Miró, Oscar|||0000-0002-7924-9751
To investigate whether the timing of a previous hospital admission for acute heart failure (AHF) is a prognostic factor for AHF patients revisiting the emergency department (ED) in the subsequent 12-month follow-up. All ED AHF patients enrolled in the previously described EAHFE registry were stratified by the presence or absence of an AHF hospitalization admission in the prior 12 months. The primary outcome was 12-month all-cause mortality post ED visit. Secondary end points were hospital admission, prolonged hospitalization (> 7 days), mortality during hospitalization and a 90-day post-discharge adverse composite event (ACE) rate, defined as ED revisits due to AHF, hospitalizations due to AHF, or all-cause mortality. Outcomes were adjusted for baseline and AHF episode characteristics.Of 5,757 patients included, the median age was 84 years (IQR 77-88); 57% were women, and 3,759 (65.3%) had an AHF hospitalization in the previous 12 months. The 12-month mortality was 37% (41.7% vs. 28.3% p < 0.001), hospital admission was 76.1% (78.8% vs. 71.1% p < 0.001) ACE was 60.2% (65.1% vs. 50.5% p < 0.001). In the adjusted analysis, patients with AHF hospitalization in the prior 12 months had a higher mortality (HR = 1.41; 95% CI 1.27-1.56), 90-day ACE rate (HR = 1.45: 95% CI 1.32-1.59), and more hospital admissions (OR = 1.32; 95% CI 1.16-1.51), with shorter times since the previous hospitalization being related to the outcomes analyzed. One-year mortality, adverse events at 90 days, and readmission rates are increased in ED AHF patients previously admitted within the last 12 months.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation

  • Kervella, Delphine|||0000-0001-8069-6105
  • Casanova Ferrer, Franc
  • Kotton, Camille N
  • Donadeu, Laura|||0000-0002-5089-5047
  • Kumar, Deepali|||0000-0003-1961-0477
  • Pineda, Silvia|||0000-0003-4017-1480
  • Crespo, Elena
  • Meneghini, Maria|||0000-0001-7307-923X
  • González-Costelo, José
  • García Romero, Elena|||0000-0003-4090-6571
  • Lladó, Laura|||0000-0002-3717-3306
  • Cachero, Alba|||0000-0002-0010-4534
  • Melilli, Edoardo|||0000-0001-6965-3745
  • Torres, Irina B.|||0000-0003-3304-0810
  • Martínez Lacalle, Anna
  • Castañeda, Zaira|||0000-0001-7526-1078
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Giral, Magali|||0000-0001-7641-1592
  • Brouard, Sophie
  • Girardin, François R.
  • Villard, Jean
  • Budde, K.
  • Lefaucheur, Carmen
  • Loupy, Alexandre|||0000-0003-3388-7747
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard, Oriol|||0000-0001-9468-7920
The interferon gamma (IFN-γ) enzyme-linked immunosorbent spot is a highly sensitive immune assay that enables the assessment of cytomegalovirus (CMV)-specific cell-mediated immunity (CMI) and can identify at-risk transplant patients of CMV infection; however, its clinical implementation remains elusive. We developed a novel CMV-CMI risk-score based on the standardized T-SPOT.CMV assay against 2 CMV antigens (immediate-early protein 1 [IE-1] and 65 kDa phosphoprotein [pp65]), a biomarker predicting CMV infection, both high viral replication, and disease by performing a pooled analysis of 570 kidney transplants participating in different clinical trials and subsequently validating it in 146 consecutives solid organ transplants (SOT) in an interventional trial. By incorporating clinical variables into the CMV-CMI risk-score, we built an integrative prognostic system quantifying the risk of CMV infection (CMV-PrognosTIC score) using elastic net penalized regression analysis. In the pooled derivation cohort, whereas specific IE-1/pp65-specific CMV-CMI frequencies independently correlated with high risk of CMV infection (areas under the curve [AUCs]: 0.694, P < 0.0001; 0.719, P < 0.0001, respectively), by combining both responses, 3 CMV-CMI risk-scores appeared, accurately discriminating low-risk (LR) from intermediate-risk (IR) and high-risk (HR) patients (98.7% negative predictive value [NPV], 97.2% sensitivity). Its prospective implementation guiding decision-making in an independent SOT cohort confirmed the very high NPV and sensitivity identifying LR patients. By integrating type of preventive therapy, patient age, and donor (D) and recipient (R) CMV-serostatus to the CMV-CMI risk-score, we generated a global risk-prognostic model showing accurate discrimination and calibration in both derivation (AUC: 0.807) and validation cohorts (AUC: 0.719). Conclusion: We developed a robust CMV-PrognosTIC score to quantify the risk of CMV infection in SOT, which may be readily implemented in clinical transplantation to personalize CMV preventive therapies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma

  • Ligero, Marta
  • Carpio Segura, Cecilia del Carmen|||0000-0001-9346-0134
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • Iraola-Truchuelo, Josu|||0000-0002-9909-3715
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Perez-Lopez, Raquel|||0000-0002-9176-0130
  • Barba, Pere|||0000-0001-7076-7969
  • Simó Perdigó, Marc|||0000-0002-3982-8759
  • Balaguer-Montero, Maria
  • Navarro Garcés, Víctor|||0000-0001-6925-4605
  • Sánchez-Salinas, Mario Andrés
  • Sala-Llonch, Roser
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment option for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). However, only a subset of patients will present long-term benefit. In this study, we explored the potential of PET-based radiomics to predict treatment outcomes with the aim of improving patient selection for CAR T-cell therapy. We conducted a single-center study including 93 consecutive R/R LBCL patients who received a CAR T-cell infusion from 2018 to 2021, split in training set (73 patients) and test set (20 patients). Radiomics features were extracted from baseline PET scans and clinical benefit was defined based on median progression-free survival (PFS). Cox regression models including the radiomics signature, conventional PET biomarkers and clinical variables were performed for most relevant outcomes. A radiomics signature including 4 PET-based parameters achieved an AUC = 0.73 for predicting clinical benefit in the test set, outperforming the predictive value of conventional PET biomarkers (total metabolic tumor volume [TMTV]: AUC = 0.66 and maximum standardized uptake value [SUV]: AUC = 0.59). A high radiomics score was also associated with longer PFS and OS in the multivariable analysis. In conclusion, the PET-based radiomics signature predicted efficacy of CAR T-cell therapy and outperformed conventional PET biomarkers in our cohort of LBCL patients. In patients with large B-cell lymphoma treated with CAR T-cells,radiomics quantification of the PET component allows for better prediction of short term recurrence(3-moths PFS)than conventional SUVmax and Total Metabolic Tumor Volume(TMTV) The combination of Radiomics signature with clinical data allows for better patient stratification.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old

  • Ceriello, Chiara
  • Torres Bonafonte, Olga H.|||0000-0002-0305-8211
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vera-Campuzano, Elena
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Álvarez-Sánchez, Esther|||0009-0002-8760-2153
  • Lorente, Oriol
  • Carreras, Mireia
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Background and Objectives: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called “very old,” remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. Methods: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic–based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. Results: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88–0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (−0.47 vs −0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05–2.13, p = 0.026). Discussion: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.
Repisalud
Publication Artículo científico (JournalArticle)

Impact of Frailty and Disability on 30-Day Mortality in Older Patients With Acute Heart Failure.

  • Martín-Sánchez, Francisco Javier
  • Rodríguez-Adrada, Esther
  • Vidan, Maria Teresa
  • Llopis García, Guillermo
  • González Del Castillo, Juan
  • Rizzi, Miguel Alberto
  • Alquezar, Aitor
  • Piñera, Pascual
  • Lázaro Aragues, Paula
  • Llorens, Pere
  • Herrero, Pablo
  • Jacob, Javier
  • Gil, Víctor
  • Fernández, Cristina
  • Bueno, Hector
  • Miró, Òscar
The objectives were to determine the impact of frailty and disability on 30-day mortality and whether the addition of these variables to HFRSS EFFECT risk score (FBI-EFFECT model) improves the short-term mortality predictive capacity of both HFRSS EFFECT and BI-EFFECT models in older patients with acute decompensated heart failure (ADHF) atended in the emergency department. We performed a retrospective analysis of OAK Registry including all consecutive patients ≥65 years old with ADHF attended in 3 Spanish emergency departments over 4 months. FBI-EFFECT model was developed by adjusting probabilities of HFRSS EFFECT risk categories according to the 6 groups (G1: non frail, no or mildly dependent; G2: frail, no or mildly dependent; G3: non frail, moderately dependent; G4: frail, moderately dependent; G5: severely dependent; G6: very severely dependent).We included 596 patients (mean age: 83 [SD7]; 61.2% females). The 30-day mortality was 11.6% with statistically significant differences in the 6 groups (p < 0.001). After adjusting for HFRSS EFFECT risk categories, we observed a progressive increase in hazard ratios from groups G2 to G6 compared with G1 (reference). FBI-EFFECT had a better prognostic accuracy than did HFRSS EFFECT (log-rank p < 0.001; Net Reclassification Improvement [NRI] = 0.355; p < 0.001; Integrated Discrimination Improvement [IDI] = 0.052; p ;< 0.001) and BI-EFFECT (log-rank p = 0.067; NRI = 0.210; p = 0.033; IDI = 0.017; p = 0.026). In conclusion, severe disability and frailty in patients with moderate disability are associated with 30-day mortality in ADHF, providing additional value to HFRSS EFFECT model in predicting short-term prognosis and establishing a care plan.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Tiempo de estancia prolongado en los pacientes ingresados por insuficiencia cardiaca aguda

  • Martín-Sánchez, F.J.
  • Carbajosa, V.
  • Llorens, P.
  • Herrero, P.
  • Jacob, J.
  • Miró, Ò.
  • Fernández, C.
  • Bueno, H.
  • Calvo, E.
  • Ribera Casado, J.M.
  • Adrada, E.R.
  • Lage, M.C.
  • Muñoz, M.
  • Coloma, E.
  • Gil, V.
  • Escoda, R.
  • Pérez-Durá, M.J.
  • Salvo, E.
  • Pavón, J.
  • álvarez, A.B.
  • Noval, A.
  • Torres, J.M.
  • López-Grima, M.L.
  • Valero, A.
  • Juan-Gómez, M.A.
  • Aguirre, A.
  • Pedragosa, M.A.
  • Alonso, M.I.
  • Sancho, H.
  • Ruiz, F.
  • Giménez, A.
  • Franco, J.M.
  • Pardo, S.
  • Mecina, A.B.
  • Rocío, Merino Genicio
  • Tost, J.
  • Penco, B.F.
  • Sánchez, A.L.
  • Fabregat, J.
  • Epelde, F.
  • Sánchez, S.
  • Piñera, P.
  • Garate, R.T.
  • Alquezar, A.
  • Rizzi, M.A.
  • Cabello, I.
  • Richard, F.
  • Lucas, J.
  • álvarez, J.V.
  • Morilla, A.A.
  • Irimia, A.
  • e, Isis Ba
  • Fuentes, M.
  • Gil, C.
Objetivo: Identificar los factores asociados al tiempo de estancia hospitalaria prolongado en pacientes ingresados/as por insuficiencia cardiaca aguda. Método: Estudio observacional de cohorte multipropósito que incluyó pacientes del registro EAHFE (Epidemiology Acute Heart Failure in Emergency) ingresados/as por insuficiencia cardiaca aguda en 25 hospitales españoles. Se recogieron variables demográficas y clínicas, el día y el lugar del ingreso. La variable resultado principal fue el tiempo de estancia hospitalaria mayor que la mediana. Resultados: Se incluyeron 2400 pacientes con una edad media de 79, 5 (±9, 9) años, de los cuales 1334 (55, 6%) eran mujeres. Quinientos noventa (24, 6%) ingresaron en la unidad de corta estancia (UCE), 606 (25, 2%) en cardiología y 1204 (50, 2%) en medicina interna o geriatría. La mediana del tiempo de estancia hospitalaria fue de 7, 0 (intervalo intercuartílico: 4-11 días). Cincuenta y ocho (2, 4%) pacientes fallecieron y 562 (23, 9%) sufrieron un reingreso a los 30 días tras el alta. Los factores independientes asociados a un tiempo de estancia hospitalaria prolongado fueron la enfermedad pulmonar obstructiva crónica, ser portador de un dispositivo, tener un factor precipitante desconocido o no común, la presencia en urgencias de insuficiencia renal, hiponatremia y anemia, no ingresar en una UCE o no disponer de dicha unidad e ingresar un lunes, martes o miércoles; y los asociados a un tiempo de estancia hospitalaria =7 días fueron la hipertensión arterial y tener como factor precipitante una crisis hipertensiva o la falta de adherencia al tratamiento. El área bajo la curva del modelo mixto ajustado al centro fue de 0, 78 (intervalo de confianza del 95%: 0, 76-0, 80; p <0, 001).Conclusiones: Hay una serie de factores asociados con un tiempo de estancia hospitalaria prolongado que deben ser considerados para la gestión del proceso de la insuficiencia cardiaca aguda. Objective: To identify the factors associated with prolonged length of hospital stay in patients admitted for acute heart failure. Methods: Multipurpose observational cohort study including patients from the EAHFE registry admitted for acute heart failure in 25 Spanish hospitals. Data were collected on demographic and clinical variables and on the day and place of admission. The primary outcome was length of hospital stay longer than the median. Results: We included 2, 400 patients with a mean age of 79.5 (9.9) years; of these, 1, 334 (55.6%) were women. Five hundred and ninety (24.6%) were admitted to the short stay unit (SSU), 606 (25.2%) to cardiology, and 1, 204 (50.2%) to internal medicine or gerontology. The mean length of hospital stay was 7.0 (RIC 4-11) days. Fifty-eight (2.4%) patients died and 562 (23.9%) were readmitted within 30 days after discharge. The factors associated with prolonged length of hospital stay were chronic pulmonary disease; being a device carrier; having an unknown or uncommon triggering factor; the presence of renal insufficiency, hyponatremia and anaemia in the emergency department; not being admitted to an SSU or the lack of this facility in the hospital; and being admitted on Monday, Tuesday or Wednesday. The factors associated with length of hospital stay=7days were hypertension, having a hypertensive episode, or a lack of treatment adherence. The area under the curve of the mixed model adjusted to the center was 0.78 (95% CI: 0.76-0.80; p < 0.001). Conclusions: A series of factors is associated with prolonged length of hospital stay and should be taken into account in the management of acute heart failure.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry

  • Miró, Ò.
  • Martínez, G.
  • Masip, J.
  • Gil, V.
  • Martín-Sánchez, F.J.
  • Llorens, P.
  • Herrero-Puente, P.
  • Sánchez, C.
  • Richard, F.
  • Lucas-Invernón, J.
  • Garrido, J.M.
  • Mebazaa, A.
  • Ríos, J.
  • Peacock, W.F.
  • Hollander, J.E.
  • Jacob, J.
  • Fuentes, M.
  • Gil, C.
  • Alonso, H.
  • Garmila, P.
  • Adrada, E.R.
  • Escoda, R.
  • Xipell, C.
  • Sánchez, C.
  • Gaytan, J.M.
  • Salvo, E.
  • Pérez-Durá, M.J.
  • Noval, A.
  • Torres, J.M.
  • Gómez, M.J.
  • López-Grima, M.L.
  • Valero, A.
  • Aguirre, A.
  • Pedragosa, M.
  • Alonso, M.I.
  • Ruiz, F.
  • Franco, J.M.
  • Diaz, E.
  • Mecina, A.B.
  • Tost, J.
  • Sánchez, S.
  • Piñera, P.
  • Garate, R.T.
  • Alquezar, A.
  • Rizzi, M.A.
  • Herrera, S.
  • Cabello, I.
  • Pérez, J.M.
  • Diez, M.P.L.
  • Alvarez, J.V.
  • Gonzalez, M.S.
  • Román, J.J.G.
  • Carratalá, J.M.
  • Brouzet, B.
  • Marquina, V.
  • Jiménez, I.
  • Hernández, N.
  • Román, F.
  • Andueza, J.A.
  • Romero, R.
  • Calvache, R.
  • Lorca, M.T.
  • Calderón, L.
  • Arriaga, B.A.
  • Sierra, B.
  • Mojarro, E.M.
  • Bécquer, L.T.
  • Garcia, L.L.
  • LaSalle, G.C.
  • Urbano, C.A.
  • Ferrer, E.S.
  • on, behalf, of, the, ICA-SEMES, Research, Group, Researchers
Objective: To assess the effects of non-invasive ventilation (NIV) in emergency department (ED) patients with acute heart failure (AHF) on short term outcomes. Methods: Patients from the EAHFE Registry (a multicenter, observational, multipurpose, cohort-designed database including consecutive AHF patients in 41 Spanish EDs) were grouped based on NIV treatment (NIV+ and NIV–groups). Using propensity score (PS) methodology, we identified two subgroups of patients matched by 38 covariates and compared regarding 30-day survival (primary outcome). Interaction was investigated for age, sex, ischemic cardiomyopathy, chronic obstructive pulmonary disease, AHF precipitated by an acute coronary syndrome (ACS), AHF classified as hypertensive or acute pulmonary edema (APE), and systolic blood pressure (SBP). Secondary outcomes were intensive care unit (ICU) admission; mechanical ventilation; in-hospital, 3-day and 7-day mortality; and prolonged hospitalization (>7 days). Results: Of 11, 152 patients from the EAHFE (age (SD): 80 (10) years; 55.5% women), 718 (6.4%) were NIV+ and had a higher 30-day mortality (HR = 2.229; 95%CI = 1.861–2.670) (p < 0.001). PS matching provided 2 groups of 490 patients each with no significant differences in 30-day mortality (HR = 1.239; 95%CI = 0.905–1.696) (p = 0.182). Interaction analysis suggested a worse effect of NIV on elderly patients (>85 years, p < 0.001), AHF associated with ACS (p = 0.045), and SBP < 100 mmHg (p < 0.001). No significant differences were found in the secondary endpoints except for more prolonged hospitalizations in NIV+ patients (OR = 1.445; 95%CI = 1.122–1.862) (p = 0.004). Conclusion: The use of NIV to treat AHF in ED is not associated with improved mortality outcomes and should be cautious in old patients and those with ACS and hypotension.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes

  • Javaloyes, P.
  • Miro, O.
  • Gil, V.
  • Martin-Sanchez, F.J.
  • Jacob, J.
  • Herrero, P.
  • Takagi, K.
  • Alquezar-Arbe, A.
  • Diez, M.P.L.
  • Martin, E.
  • Bibiano, C.
  • Escoda, R.
  • Gil, C.
  • Fuentes, M.
  • Garcia, G.L.
  • Perez, J.M.A.
  • Jerez, A.
  • Tost, J.
  • Llauger, L.
  • Romero, R.
  • Garrido, J.M.
  • Rodriguez-Adrada, E.
  • Sanchez, C.
  • Rossello, X.
  • Parissis, J.
  • Mebazaa, A.
  • Chioncel, O.
  • Llorens, P.
  • Alonso, H.
  • Perez-Llantada, E.
  • Cadenas, M.S.
  • Xipell, C.
  • Perez-Dura, M.J.
  • Salvo, E.
  • Pavon, J.
  • Noval, A.
  • Torres, J.M.
  • Lopez-Grima, M.L.
  • Valero, A.
  • Juan, M.A.
  • Aguirre, A.
  • Pedragosa, M.A.
  • Maso, S.M.
  • Alonso, M.I.
  • Ruiz, F.
  • Franco, J.M.
  • Mecina, A.B.
  • Berenguer, M.
  • Donea, R.
  • Ramon, S.S.
  • Rodriguez, V.C.
  • Pinera, P.
  • Nicolas, J.A.S.
  • Garate, R.T.
  • Rizzi, M.A.
  • Herrera, S.
  • Cabello, I.
  • Haro, A.
  • Richard, F.
  • Diez, M.P.L.
  • Alvarez, J.V.
  • Garcia, B.P.
  • Garcia, M.G.
  • Gonzalez, M.S.
  • Marquina, V.
  • Jimenez, I.
  • Hernandez, N.
  • Brouzet, B.
  • Espinosa, B.
  • Andueza, J.A.
  • Ruiz, M.
  • Calvache, R.
  • Serralta, M.T.L.
  • Jave, L.E.C.
  • Amores Arriaga, B.
  • Bergua, B.S.
  • Mojarro, E.M.
  • Jimenez, B.S.A.
  • Becquer, L.T.
  • Burillo, G.
  • Garcia, L.L.
  • LaSalle, G.C.
  • Urbano, C.A.
  • Soto, A.B.G.
  • Padial, E.D.
  • Ferrer, E.S.
  • Lucas-Imbernon, F.J.
  • Gaya, R.
  • Mir, M.
  • Rodriguez, B.
  • Carballo, J.L.
  • Miranda, B.R.
Objective To compare the clinical characteristics and outcomes of patients with acute heart failure (AHF) according to clinical profiles based on congestion and perfusion determined in the emergency department (ED). Methods and results Overall, 11 261 unselected AHF patients from 41 Spanish EDs were classified according to perfusion (normoperfusion = warm; hypoperfusion = cold) and congestion (not = dry; yes = wet). Baseline and decompensation characteristics were recorded as were the main wards to which patients were admitted. The primary outcome was 1-year all-cause mortality; secondary outcomes were need for hospitalisation during the index AHF event, in-hospital all-cause mortality, prolonged hospitalisation, 7-day post-discharge ED revisit for AHF and 30-day post-discharge rehospitalisation for AHF. A total of 8558 patients (76.0%) were warm+ wet, 1929 (17.1%) cold+ wet, 675 (6.0%) warm+ dry, and 99 (0.9%) cold+ dry; hypoperfused (cold) patients were more frequently admitted to intensive care units and geriatrics departments, and warm+ wet patients were discharged home without admission. The four phenotypes differed in most of the baseline and decompensation characteristics. The 1-year mortality was 30.8%, and compared to warm+ dry, the adjusted hazard ratios were significantly increased for cold+ wet (1.660; 95% confidence interval 1.400-1.968) and cold+ dry (1.672; 95% confidence interval 1.189-2.351). Hypoperfused (cold) phenotypes also showed higher rates of index episode hospitalisation and in-hospital mortality, while congestive (wet) phenotypes had a higher risk of prolonged hospitalisation but decreased risk of rehospitalisation. No differences were observed among phenotypes in ED revisit risk. Conclusions Bedside clinical evaluation of congestion and perfusion of AHF patients upon ED arrival and classification according to phenotypic profiles proposed by the latest European Society of Cardiology guidelines provide useful complementary information and help to rapidly predict patient outcomes shortly after ED patient arrival.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Influence of the length of hospitalisation in post-discharge outcomes in patients with acute heart failure: Results of the LOHRCA study

  • Miró, Ò.
  • Padrosa, J.
  • Takagi, K.
  • Gayat, É.
  • Gil, V.
  • Llorens, P.
  • Martín-Sánchez, F.J.
  • Herrero-Puente, P.
  • Jacob, J.
  • Montero, M.M.
  • Tost, J.
  • Díez, M.P.L.
  • Traveria, L.
  • Torres-Gárate, R.
  • Alonso, M.I.
  • Agüera, C.
  • Valero, A.
  • Javaloyes, P.
  • Peacock, W.F.
  • Bueno, H.
  • Mebazaa, A.
  • Fuentes, M.
  • Gil, C.
  • Alonso, H.
  • Garmila, P.
  • García, G.L.
  • Yáñez-Palma, M.C.
  • López, S.I.
  • Escoda, R.
  • Xipell, C.
  • Sánchez, C.
  • Gaytan, J.M.
  • Pérez-Durá, M.J.
  • Salvo, E.
  • Pavón, J.
  • Noval, A.
  • Torres, J.M.
  • López-Grima, M.L.
  • Juan, M.Á.
  • Aguirre, A.
  • Morales, J.E.
  • Masó, S.M.
  • Ruiz, F.
  • Franco, J.M.
  • Mecina, A.B.
  • Sánchez, S.
  • Carbajosa, V.
  • Piñera, P.
  • Nicolás, J.A.S.
  • Garate, R.T.
  • Alquezar, A.
  • Rizzi, M.A.
  • Herrera, S.
  • Roset, A.
  • Cabello, I.
  • Richard, F.
  • Pérez, J.M.Á.
  • Diez, M.P.L.
  • Álvarez, J.V.
  • García, B.P.
  • Sánchez González, M.G.G.Y.
  • Marquina, V.
  • Jiménez, I.
  • Hernández, N.
  • Brouzet, B.
  • Ramos, S.
  • López, A.
  • Andueza, J.A.
  • Romero, R.
  • Ruíz, M.
  • Calvache, R.
  • Lorca, M.T.
  • Calderón, L.
  • Arriaga, B.A.
  • Sierra, B.
  • Mojarro, E.M.
  • Bécquer, L.T.
  • Burillo, G.
  • García, L.L.
  • LaSalle, G.C.
  • Urbano, C.A.
  • Soto, A.B.G.
  • Padial, E.D.
  • Ferrer, E.S.
  • Garrido, M.
  • Lucas, F.J.
  • Gaya, R.
  • Bibiano, C.
  • Mir, M.
  • Rodríguez, B.
  • Sánchez, N.
  • Carballo, J.L.
  • Rodríguez-Adrada, E.
  • Rodríguez, B.
Objective: To investigate the relationship between length of hospitalisation (LOH) and post-discharge outcomes in acute heart failure (AHF) patients and to ascertain whether there are different patterns according to department of initial hospitalisation. Methods: Consecutive AHF patients hospitalised in 41 Spanish centres were grouped based on the LOH (<6/6-10/11-15/>15 days). Outcomes were defined as 90-day post-discharge all-cause mortality, AHF readmissions, and the combination of both. Hazard ratios (HRs), adjusted by chronic conditions and severity of decompensation, were calculated for groups with LOH >6 days vs. LOH <6 days (reference), and stratified by hospitalisation in cardiology, internal medicine, geriatrics, or short-stay units. Results: We included 8563 patients (mean age: 80 (SD = 10) years, 55.5% women), with a median LOH of 7 days (IQR 4–11): 2934 (34.3%) had a LOH <6 days, 3184 (37.2%) 6–10 days, 1287 (15.0%) 11–15 days, and 1158 (13.5%) >15 days. The 90-day post-discharge mortality was 11.4%, readmission 32.2%, and combined endpoint 37.4%. Mortality was increased by 36.5% (95%CI = 13.0–64.9) when LOH was 11–15 days, and by 72.0% (95%CI = 42.6–107.5) when >15 days. Conversely, no differences were found in readmission risk, and the combined endpoint only increased 21.6% (95%CI = 8.4–36.4) for LOH >15 days. Stratified analysis by hospitalisation departments rendered similar post-discharge outcomes, with all exhibiting increased mortality for LOH >15 days and no significant increments in readmission risk. Conclusions: Short hospitalisations are not associated with worse outcomes. While post-discharge readmissions are not affected by LOH, mortality risk increases as the LOH lengthens. These findings were similar across hospitalisation departments.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

  • Zacchi, Francesca
  • Semidey Raven, Maria Eugenia
  • Maldonado, Xavier
  • Perez-Lopez, Raquel
  • Mateo, Joaquin
  • Macarena, Gonzalez
  • Carles, Joan
Bone metastases; Bone response; Metastatic castration-resistant prostate cancer, Metástasis óseas; Respuesta ósea; Cáncer de próstata resistente a la castración metastásico, Metàstasis òssies; Resposta òssia; Càncer de pròstata resistent a la castració metastàtic, Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients' outcomes are heterogenous, and there is lack of validated predictive biomarkers of response, while biomarkers for early identification of patients who benefit from treatment are limited. This case report describes a remarkable and durable response to Ra-223 in a CRPC patient with bone metastases who had rapidly progressed to many previous therapies; this response is now lasting for 5 years even after having stopped backbone androgen deprivation therapy (ADT). Here, we present the clinical course of this exceptional response, as well as comprehensive genomic and histopathology analyses on sequential biopsies acquired before and after therapy. Additionally, we review current knowledge on predictive and response biomarkers to Ra-223 in metastatic prostate cancer., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge funding from CRIS Cancer Foundation (grant TCL_2020-10 to JM) and Fundación AECC (LABAE20019MATE to JM) and FERO Foundation. RP-L is supported by LaCaixa Foundation, a CRIS Foundation Talent Award TALENT19-05, the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud PI18/01395 and PI21/01019 and the Prostate Cancer Foundation 18YOUN19.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI

  • Macarro, Carlos
  • Bernatowicz, Kinga
  • García Ruiz, Alonso
  • Monreal-Agüero, Camilo
  • Corral Gámez, Juanfra
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Serna, Garazi
  • Simonetti, Sara
  • Roson Gradaille, Nuria
  • Vieito , Maria
  • ESCOBAR, MANUEL
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cuantificación microestructural de tumores; Aprendizaje automático; Resonancia magnética de difusión-relajación, Quantificació microestructural del tumor; Aprenentatge automàtic; Ressonància magnètica de difusió-relaxació, Tumor microstructural quantification; Machine learning; Diffusion-relaxation magnetic resonance imaging, We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron Campus. We would also like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO acknowledges the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe” (to R.P.L.). RPL is supported by “la Caixa” Foundation, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research has been funded by the CaixaResearch Advanced Oncology Research Program supported by “La Caixa” Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”, funding F.G. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). C.M. is supported by the Asociación Española Contra el Cancer (PRYCO211023SERR). VHIO is also grateful to the Generalitat de Catalunya, Comissió Interdepartamental de Recerca i Innovació Tecnològica.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

  • Palombo, Marco
  • Navarro-Garcia, Daniel
  • Macarro, Carlos
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Grussu, Francesco
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Casanova-Salas, Irene
  • Barba, Ignasi
  • Simonetti, Sara
  • Serna, Garazi
  • Voronova, Anna
  • Corral Gámez, Juanfra
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • Mateo, Joaquin
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Liver tumour cell; In vivo diffusion MRI, Células tumorales hepáticas; Resonancia magnética de difusión in vivo, Cèl·lules tumorals hepàtiques; Ressonància magnètica de difusió in vivo, Background: Innovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology. Methods: We compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types. Results: We select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10-5 for tumour volume regression), and iii) that distinguish melanoma (N = 8) from colorectal cancer (N = 13) (p = 0.011 for intra-cellular fraction). Conclusions: Our biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology., We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d’Hebron University Hospital and at the Vall d’Hebron Institute of Oncology in Barcelona (Spain), without whom this study would not have been possible. We are also thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance, and to past and present members of the Radiomics group for useful discussion and advice. Finally, we would like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI21/01019” and co-funded by the European Union. Data acquisition was also supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), ISCIII (PI18/01395), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The project that gave rise to these results received the support of a fellowship from”la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G. and A.V.) and “LCF/BQ/PI20/11760033” (funding I.C.S). I.C.S. also receives the support of the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). C.M. is funded by the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR). Funding supported personnel, data acquisition and processing, and dissemination. Funders did not influence the content of the manuscript and the decision to submit it in its current form for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response

  • Navarro-Garcia, Daniel
  • Klümper, Niklas
  • Macarro, Carlos
  • Sanz, Marta
  • Alonso, Guzman
  • Lostes Bardaji, M Julia
  • Grussu, Francesco
  • Zatse, Christina
  • Hernando-Calvo, Alberto
  • Vieito , Maria
  • Brana, Irene
  • Mirallas, Oriol
  • Galvao, Vladimir
  • Pretelli, Giulia
  • Oberoi, Arjun
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Biomarcador; Inhibidor de puntos de control inmunitario; Inmunoterapia, Biomarcador; Inhibidor del punt de control immunitari; Immunoteràpia, Biomarker; Immune checkpoint inhibitor; Immunotherapy, Background The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics., This research has been supported by PREDICT sponsored by AstraZeneca. RP-L is also supported by a CRIS Foundation Talent Award (TALENT19-05), Asociacion Espanola Contra el Cancer (AECC) (PRYCO211023SERR), the FERO Foundation, “la Caixa” Foundation, Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). FG receives the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010". Vall d’Hebron Institut d’Oncologia (VHIO) authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Centre of Excellence Severo Ochoa (CEX2020-001024-S/AEI/ 10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Generalitat de Catalunya CERCA Programme for their support of this research. We would like to acknowledge all the patients who participated in this and other clinical research projects for their contribution to science. AHC would like to acknowledge Contrato Rio Hortega 2024 and Beca Gilead a la Investigación Biomedica.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?

  • Gielen, Bente
  • Prior, Olivia
  • Ligero, Marta
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Cresta Morgado, Pablo
  • Navarro Garces, Victor
Biomarkers; Immunotherapy; Cancer, Biomarcadors; Immunoteràpia; Càncer, Biomarcadores; Inmunoterapia; Cáncer, The search for understanding immunotherapy response has sparked interest in diverse areas of oncology, with artificial intelligence (AI) and radiomics emerging as promising tools, capable of gathering large amounts of information to identify suitable patients for treatment. The application of AI in radiology has grown, driven by the hypothesis that radiology images capture tumor phenotypes and thus could provide valuable insights into immunotherapy response likelihood. However, despite the rapid growth of studies, no algorithms in the field have reached clinical implementation, mainly due to the lack of standardized methods, hampering study comparisons and reproducibility across different datasets. In this review, we performed a comprehensive assessment of published data to identify sources of variability in radiomics study design that hinder the comparison of the different model performance and, therefore, clinical implementation. Subsequently, we conducted a use-case meta-analysis using homogenous studies to assess the overall performance of radiomics in estimating programmed death-ligand 1 (PD-L1) expression. Our findings indicate that, despite numerous attempts to predict immunotherapy response, only a limited number of studies share comparable methodologies and report sufficient data about cohorts and methods to be suitable for meta-analysis. Nevertheless, although only a few studies meet these criteria, their promising results underscore the importance of ongoing standardization and benchmarking efforts. This review highlights the importance of uniformity in study design and reporting. Such standardization is crucial to enable meaningful comparisons and demonstrate the validity of biomarkers across diverse populations, facilitating their implementation into the immunotherapy patient selection process., This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021). RPL is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociacion Española Contra el Cancer (AECC) (PRYCO211023SERR). ML is supported by the PERIS PIF-Salut Grant. OP is supported by a La Caixa INPhINIT Fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ESR Essentials: diffusion-weighted MRI—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology

  • Palombo, Marco
  • Tang, Guoheng
  • Le Bihan, Denis
  • Nilsson, Markus
  • Grussu, Francesco
  • Perez-Lopez, Raquel
Diffusion magnetic resonance imaging; Human body; Human brain, Resonancia magnética de difusión; Cuerpo humano; Cerebro humano, Ressonància magnètica de difusió; Cos humà; Cervell humà, Diffusion-weighted imaging (DWI) offers critical insights into tissue microstructure through the assessment of water molecule random displacements and plays a central role in the assessment of neoplastic and non-neoplastic diseases. To successfully implement and use DWI in clinical practice, guidelines for acquisition, interpretation of image contrast and of artefacts should be followed, taking the disease process and body part into account. We recommend covering a b-value range of 0–1000 s/mm2 in the brain (along at least six directions for white matter), and 50–800 s/mm2 in the body. Available acquisition acceleration options should be used to reduce repetition time (TR), echo time (TE), and echo-planar imaging (EPI) distortions, while considering the penalty in signal-to-noise ratio (SNR) and image sharpness. DW images and the apparent diffusion coefficient (ADC) map should be read jointly for the clinical interpretation. Areas of slower diffusion are hyperintense on DW images and hypointense on the ADC map, and vice versa. Magnetic susceptibility distortions and signal drop-outs or pile-ups are particularly pronounced at air-tissue or metal-tissue interfaces and may obscure areas of interest or hinder the co-localisation with structural scans. By following these guidelines and recommendations, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications. Key Points This article provides an overview of DWI principles, clinical applications, potential pitfalls, and emerging advances, alongside expert recommendations for optimal implementation. We provide key considerations tailored to specific applications (neuro and whole-body imaging), including protocol optimisation, adherence to established guidelines, and quality assurance measures to minimise artefacts and ensure reproducibility. By following the guidelines and recommendations summarised in this work, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications., The authors state that this work has not received any funding. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2 and the Medical Research Council research grant MR/W031566/1. R.P.-L. is supported by ‘la Caixa’ Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). F.G. receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. I.O.J. is supported by the SNSF Eccellenza fellowship #194260. M.N. is supported by the Swedish Cancer Foundation (FO2024-0335-HK-73) and the Swedish Science Council (2024-04968).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

  • Zatse, Christina
  • Garazi, Serna
  • Bernatowicz, Kinga
  • Amat Ferrer, Ramon
  • Prior, Olivia
  • Frigola Rissech, Joan
  • Ligero, Marta
  • Grussu, Francesco
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • ESCOBAR, MANUEL
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • FELIP, ENRIQUETA
Computed tomography; Immunotherapy; Tumor microenvironment, Tomografía computarizada; Inmunoterapia; Microambiente tumoral, Tomografia computeritzada; Immunoteràpia; Microambient tumoral, Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies have triggered the exploration of non-invasive alternatives, such as radiomics, to comprehensively evaluate TIME across diverse cancers. To address these challenges, we develop an ICI response signature by integrating radiomics with T cell-inflamed gene-expression profiles. Methods: We conducted a pan-cancer investigation into the utility of radiomics for TIME assessment, including 1360 tumors from 428 patients. Leveraging contrast-enhanced CT images, we characterized TIME through RNA gene expression analysis, using the T cell-inflamed gene expression signature. Subsequently, a pan-cancer CT-radiomic signature predicting inflamed TIME (CT-TIME) was developed and externally validated. Machine learning was employed to select robust radiomic features and predict inflamed TIME. The study also integrated independent cohorts with longitudinal CT images, baseline biopsies, and comprehensive immunohistochemistry panel evaluation to assess the pan-cancer biological associations, spatiotemporal landscape and clinical utility of the CT-TIME. Results: The CT-TIME signature, comprising four radiomic features linked to a T-cell inflamed microenvironment, demonstrated robust performance with AUCs (95% CI) of 0.85 (0.73 to 0.96) (training) and 0.78 (0.65 to 0.92) (external validation). CT-TIME scores exhibited positive correlations with CD3, CD8, and CD163 expression. Intrapatient analysis revealed considerable heterogeneity in TIME between tumors, which could not be assessed using biopsies. Evaluation of aggregated per-patient CT-TIME scores highlighted its promising clinical utility for dynamically assessing the immune microenvironment and predicting immunotherapy response across diverse scenarios in advanced cancer. Despite demonstrating progression disease at the first follow-up, patients within the inflamed status group, identified by CT-TIME, exhibited significantly prolonged progression-free survival (PFS), with some surpassing 5 months, suggesting a potential phenomenon of pseudoprogression. Cox models using aggregated CT-TIME scores from baseline images revealed a statistically significant reduction in the risk of PFS in the pan-cancer cohort (HR 0.62, 95% CI 0.44 to 0.88, p=0.007), and Kaplan-Meier analysis further confirmed substantial differences in PFS between patients with inflamed and uninflamed status (log-rank test p=0.009). Conclusions: The signature holds promise for impacting clinical decision-making, pan-cancer patient stratification, and treatment outcomes in immune checkpoint therapies., KB is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182). FG receives the support of a fellowship from LaCaixa Foundation (ID 100010434). The fellowship code is LCF/BQ/PR22/11920010. RP-L is supported by CRIS Cancer Foundation (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). OP was funded by Fundació “LaCaixa” (ID 100010434, code LCF/BQ/DR21/11880027).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A framework for artificial intelligence in cancer research and precision oncology

  • Perez-Lopez, Raquel
  • Reis-Filho, Jorge S.
  • Kather, Jakob Nikolas
Artificial intelligence; Precision oncology, Intel·ligència artificial; Oncologia de precisió, Inteligencia artificial; Oncología de precisión, R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR, funding C.M.). J.N.K. is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Program of the German Cancer Aid (grant #70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union’s Horizon Europe and innovation program (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. JSR-F is funded in part by the Breast Cancer Research Foundation, a Susan G Komen Leadership grant, an NIH/NCI P50 CA247749 01 grant, and an NIH/NCI grant No. P30CA008748. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

  • Balaguer-Montero, Maria
  • Marcos Morales, Adrià
  • Leiva, David
  • Atlagich, Luz M.
  • Staikoglou, Nikolaos
  • Monreal, Camilo
  • Hernando, Jorge
  • Garcia-Alvarez, Alejandro
  • Ligero, Marta
  • Zatse, Christina
  • Viaplana, Cristina
  • Mateo, Joaquin
  • Salvà, Francesc
  • Capdevila Castillon, Jaume
  • Dienstmann, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Elez, Elena
Deep learning; Imaging; Liver tumors, Aprendizaje profundo; Imágenes; Tumores hepáticos, Aprenentatge profund; Imatges; Tumors hepàtics, Liver tumors, whether primary or metastatic, significantly impact the outcomes of patients with cancer. Accurate identification and quantification are crucial for effective patient management, including precise diagnosis, prognosis, and therapy evaluation. We present SALSA (system for automatic liver tumor segmentation and detection), a fully automated tool for liver tumor detection and delineation. Developed on 1,598 computed tomography (CT) scans and 4,908 liver tumors, SALSA demonstrates superior accuracy in tumor identification and volume quantification, outperforming state-of-the-art models and inter-reader agreement among expert radiologists. SALSA achieves a patient-wise detection precision of 99.65%, and 81.72% at lesion level, in the external validation cohorts. Additionally, it exhibits good overlap, achieving a dice similarity coefficient (DSC) of 0.760, outperforming both state-of-the-art and the inter-radiologist assessment. SALSA’s automatic quantification of tumor volume proves to have prognostic value across various solid tumors (p = 0.028). SALSA’s robust capabilities position it as a potential medical device for automatic cancer detection, staging, and response evaluation., R.P.-L. is supported by “la Caixa” Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Fero Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

  • Novikov, Dmitry
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Simonetti, Sara
  • Serna, Garazi
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cancer; Capillary flow; Diffusion MRI, Cáncer; Flujo capilar; Resonancia magnética de difusión, Càncer; Flux capil·lar; Ressonància magnètica de difusió, Diffusion Magnetic Resonance Imaging (dMRI) sensitises the MRI signal to spin motion. This includes Brownian diffusion, but also flow across intricate networks of capillaries. This effect, the intra-voxel incoherent motion (IVIM), enables microvasculature characterisation with dMRI, through metrics such as the vascular signal fraction or the vascular Apparent Diffusion Coefficient (ADC) . The IVIM metrics, while sensitive to perfusion, are protocol-dependent, and their interpretation can change depending on the flow regime spins experience during the dMRI measurements (e.g., diffusive vs ballistic), which is in general not known for a given voxel. These facts hamper their practical clinical utility, and innovative vascular dMRI models are needed to enable the in vivo calculation of biologically meaningful markers of capillary flow. These could have relevant applications in cancer, as in the assessment of the response to anti-angiogenic therapies targeting tumour vessels. This paper tackles this need by introducing SpinFlowSim, an open-source simulator of dMRI signals arising from blood flow within pipe networks. SpinFlowSim, tailored for the laminar flow patterns within capillaries, enables the synthesis of highly-realistic microvascular dMRI signals, given networks reconstructed from histology. We showcase the simulator by generating synthetic signals for 15 networks, reconstructed from liver biopsies, and containing cancerous and non-cancerous tissue. Signals exhibit complex, non-mono-exponential behaviours, consistent with in vivo signal patterns, and pointing towards the co-existence of different flow regimes within the same network, as well as diffusion time dependence. We also demonstrate the potential utility of SpinFlowSim by devising a strategy for microvascular property mapping informed by the synthetic signals, and focussing on the quantification of blood velocity distribution moments and of an apparent network branching index. These were estimated in silico and in vivo, in healthy volunteers scanned at 1.5T and 3T and in 13 cancer patients, scanned at 1.5T. In conclusion, realistic flow simulations, as those enabled by SpinFlowSim, may play a key role in the development of the next-generation of dMRI methods for microvascular mapping, with immediate applications in oncology., VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L. is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05, the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178, SGR-Cat2021). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G., A.V., and A.G.). This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). The authors are thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance with MRI acquisitions, and to the GE/Siemens clinical scientists for their support with diffusion sequence characterisation. We are also thankful to patients and their families, and to Prof Roser Sala-Llonch from the University of Barcelona for useful discussion and institutional support.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI

  • Garcia Ruiz, Alonso
  • Pons-Escoda, Albert
  • Naval-Baudin, Pablo
  • Monreal-Aguero, Camilo
  • Hermann, Gretchen
  • Grussu, Francesco
  • Ligero, Marta
  • Perez-Lopez, Raquel
Deep learning; Glioblastoma; Perfusion MRI, Aprenentatge profund; Glioblastoma; Ressonància magnètica de perfusió, Aprendizaje profundo; Glioblastoma; Resonancia magnética de perfusión, Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI., This project was supported by “La Caixa” Foundation (RTI2018-095209-B-C21) and the Spanish Ministry of Science and Innovation (FIS-G64384969). R.P.-L. is supported by the Prostate Cancer Foundation Young Investigator Award, the FERO Foundation, the CRIS Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III Investigacion en Salud (PI21/01019), and the Asociacion Espanola Contra el Cancer (PRYCO211023SERR). F.G. was funded by the Government of Catalonia (Beatriu de Pinos 2020 00117 BP) and by the Fundacio LaCaixa (ID 100010434, code LCF/BQ/PR22/11920010). C.M. and A.P.-E. acknowledge support from the Instituto de Salud Carlos III-Investigación en Salud (PI20/00360). We would like to express our sincere appreciation to Javier Carmona for his valuable support and assistance in reviewing the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

  • Ramlee, Syafiq
  • Hulse, David
  • Pérez López, Raquel
  • Sala, Evis
  • Aloj, Luigi
  • Bernatowicz, Kinga
Cancer; Immune cells; Lymphocytes, Cáncer; Células inmunes; Linfocitos, Càncer; Cèl·lules immunitàries; Limfòcits, The tumour immune microenvironment influences the efficacy of immune checkpoint inhibitors. Within this microenvironment are CD8-expressing tumour-infiltrating lymphocytes (CD8+ TILs), which are an important mediator and marker of anti-tumour response. In practice, the assessment of CD8+ TILs via tissue sampling involves logistical challenges. Radiomics, the high-throughput extraction of features from medical images, may offer a novel and non-invasive alternative. We performed a systematic review of the available literature reporting radiomic signatures associated with CD8+ TILs. We also aimed to evaluate the methodological quality of the identified studies using the Radiomics Quality Score (RQS) tool, and the risk of bias and applicability with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Articles were searched from inception until 31 December 2021, in three electronic databases, and screened against eligibility criteria. Twenty-seven articles were included. A wide variety of cancers have been studied. The reported radiomic signatures were heterogeneous, with very limited reproducibility between studies of the same cancer group. The overall quality of studies was found to be less than desirable (mean RQS = 33.3%), indicating a need for technical maturation. Some potential avenues for further investigation are also discussed., This work was supported by the Cancer Research UK (CRUK) Cambridge Centre (CTRQQR-2021\100012) and the CRUK National Cancer Imaging Translational Accelerator (NCITA) (C22479/A28667); additional support was also provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014); the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; S.R. is supported by the Brunei “Sultan’s Scholar” scholarship from the Sultan Haji Hassanal Bolkiah Foundation; D.H. is supported by the Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies project (RG96994 and 831514); K.B. is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182); R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

  • Ligero, Marta
  • El Nahhas, Omar
  • SANSANO, IRENE
  • Mauchanski, Siarhei
  • Serna, Garazi
  • Viaplana, Cristina
  • Toledo, Rodrigo
  • Dienstmann, Rodrigo
  • Ramon y Cajal, Santiago
  • GARRALDA, Elena
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
Deep learning; Immunotherapy; Solid tumors, Aprenentatge profund; Immunoteràpia; Tumors sòlids, Aprendizaje profundo; Inmunoterapia; Tumores sólidos, Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1–stained slides from the non–small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1–2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96–2.2), P = 0.082] and CPS [HR: 1.2 (0.79–1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity. Significance: The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating tumor staining intensity and morphology, enables enhanced patient stratification in cancer immunotherapy compared with traditional pathologist assessment., J.N. Kather is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Programme of the German Cancer Aid (grant no. 70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union's Horizon Europe and innovation programme (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. R. Perez-Lopez is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). M. Ligero is supported by the PERIS PIF-Salut Grant. As per the ICMJE guidelines of April 2023, we hereby disclose that the following artificial intelligence tools were used to write this article: ChatGPT-4 for checking and correcting spelling and grammar.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors

  • Powers, Rani K.|||0000-0001-9501-2589
  • Culp-Hill, Rachel
  • Ludwig, Michael P.
  • Smith, Keith P.
  • Waugh, Katherine A.
  • Minter, Ross
  • Tuttle, Kathryn D.|||0000-0002-9285-5297
  • Lewis, Hannah C.
  • Rachubinski, Angela L.
  • Granrath, Ross E.|||0000-0002-9899-831X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Wilkerson, Rebecca B.
  • Kahn, Darcy E.
  • Joshi, Molishree
  • Lleó, Alberto|||0000-0002-2568-5478
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • D'Alessandro, Angelo|||0000-0002-2258-6490
  • Costello, James C.
  • Sullivan, Kelly D.
  • Espinosa, Joaquin M.
Trisomy 21 (T21) causes Down syndrome (DS), affecting immune and neurological function by ill-defined mechanisms. Here we report a large metabolomics study of plasma and cerebrospinal fluid, showing in independent cohorts that people with DS produce elevated levels of kynurenine and quinolinic acid, two tryptophan catabolites with potent immunosuppressive and neurotoxic properties, respectively. Immune cells of people with DS overexpress IDO1, the rate-limiting enzyme in the kynurenine pathway (KP) and a known interferon (IFN)-stimulated gene. Furthermore, the levels of IFN-inducible cytokines positively correlate with KP dysregulation. Using metabolic tracing assays, we show that overexpression of IFN receptors encoded on chromosome 21 contribute to enhanced IFN stimulation, thereby causing IDO1 overexpression and kynurenine overproduction in cells with T21. Finally, a mouse model of DS carrying triplication of IFN receptors exhibits KP dysregulation. Together, our results reveal a mechanism by which T21 could drive immunosuppression and neurotoxicity in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias, Update and areas of immediate need

  • Babulal, Ganesh Muneshwar
  • Quiroz, Yakeel T.|||0000-0001-9714-8244
  • Albensi, Benedict Charles
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Astell, Arlene|||0000-0002-6822-9472
  • Babiloni, Claudio|||0000-0002-5245-9839
  • Bahar-Fuchs, Alex|||0000-0002-9248-6057
  • Bell, Joanne M.
  • Bowman, Gene|||0000-0003-0111-1565
  • Brickman, Adam|||0000-0002-5125-8226
  • Chételat, G.|||0000-0002-4889-7932
  • Ciro, Carrie A.
  • Cohen, Ann D.
  • Dilworth-Anderson, Peggye
  • Dodge, Hiroko Hayama
  • Dreux, Simone
  • Edland, Steven D.
  • Esbensen, Anna J.
  • Evered, Lisbeth A.
  • Ewers, Michael|||0000-0001-5231-1714
  • Fargo, Keith N.|||0000-0002-6515-2342
  • Fortea, Juan|||0000-0002-1340-638X
  • González, Héctor M.
  • Gustafson, Deborah Ruth
  • Head, Elizabeth H.
  • Hendrix, James A.
  • Hofer, Scott M.|||0000-0001-8923-4337
  • Johnson, Leigh A.
  • Jutten, Roos J.|||0000-0002-3712-4790
  • Kilborn, Kerry W.
  • Lanctôt, Krista L.
  • Manly, Jennifer Jaie
  • Martins, Ralph|||0000-0002-4828-9363
  • Mielke, Michelle M.
  • Morris, Martha Clare
  • Murray, Melissa E.
  • Oh, E. S.
  • Parra, Mario A.
  • Rissman, Robert A.|||0000-0001-9245-8278
  • Roe, C. M.
  • Santos, Octavio A.
  • Scarmeas, N.
  • Schneider, L. S.
  • Schupf, N.
  • Sikkes, S.
  • Snyder, H. M.
  • Sohrabi, H. R.
  • Stern, Y.
  • Strydom, A.
  • Tang, Yi|||0000-0002-2594-6068
  • Terrera, Graciela Muniz
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Melo van Lent, D.
  • Weinborn, M.
  • Wesselman, L.
  • Wilcock, D. M.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • O'Bryant, S. E.
Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise "state-of-the-science" report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Conway, Olivia J.
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Carrasquillo, Minerva M.
  • Kleineidam, Luca
  • van den Akker, Erik
  • Hernández, Isabel|||0000-0001-8119-393X
  • Van Eijk, Kristel R.
  • Stringa, Najada|||0000-0001-6350-452X
  • Chen, Jason A.
  • Zettergren, Anna|||0000-0002-7182-8417
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Simón Sánchez, Javier|||0000-0001-5141-5829
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Nygaard, Marianne|||0000-0003-0703-2665
  • Blauwendraat, Cornelis|||0000-0001-9358-8111
  • Savage, Jeanne E.
  • Mengel-From, Jonas
  • Moreno-Grau, Sonia
  • Wagner, Michael
  • Fortea, Juan|||0000-0002-1340-638X
  • Keogh, Michael J.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Skoog, Ingmar
  • Friese, Manuel A.
  • Pletnikova, Olga|||0000-0001-6516-4944
  • Zulaica, Miren
  • Lage, Carmen|||0000-0003-1703-121X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Wei, Wei
  • Jeune, Bernard
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Then Bergh, Florian
  • Wang, Xue
  • Hulsman, Marc|||0000-0002-9889-3606
  • Beker, Nina
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Morris, Christopher M.
  • Indakoetxea, Begoña
  • Collij, Lyduine E.
  • Scherer, Martin
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Ironside, James W.
  • van Berckel, Bart N. M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Strickland, Samantha L.
  • Pastor, Pau|||0000-0002-7493-8777
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Boeve, Bradley
  • Petersen, Ronald C.
  • Ferman, Tanis J.
  • van Gerpen, Jay A.
  • Reinders, Marcel J. T.|||0000-0002-1148-1562
  • Uitti, Ryan J.
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Maier, Wolfgang
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Kawalia, Amit
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Boada, Mercè|||0000-0003-2617-3009
  • Zettl, Uwe K.
  • van Schoor, Natasja M.
  • Beekman, Marian|||0000-0003-0585-6206
  • Allen, Mariet
  • Masliah, Eliezer
  • de Munain, Adolfo López
  • Pantelyat, Alexander
  • Wszolek, Zbigniew K.|||0000-0001-5487-1053
  • Ross, Owen A.|||0000-0003-4813-756X
  • Dickson, Dennis W.|||0000-0001-7189-7917
  • Graff-Radford, Neill R.
  • Knopman, David
  • Rademakers, Rosa
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gasser, Thomas|||0000-0003-4882-2647
  • Chinnery, Patrick F.
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Huisman, Martijn A.
  • Troncoso, Juan
  • Moreno, Fermin|||0000-0001-5200-3164
  • Nohr, Ellen A.
  • Sørensen, Thorkild I. A.|||0000-0003-4821-430X
  • Heutink, Peter|||0000-0001-5218-1737
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Christensen, Kaare|||0000-0002-5429-5292
  • Ertekin-Taner, Nilüfer
  • Scholz, Sonja|||0000-0002-6623-0429
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Slagboom, Eline
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Holstege, Henne|||0000-0002-7688-3087
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway as drug-target.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Muñoz, Laia|||0000-0003-0578-3094
  • Camacho, Valle|||0000-0003-0748-0847
  • Lopez Mora, Diego Alfonso|||0000-0002-3533-7362
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Le Bastard, Nathalie
  • Huyck, Else
  • Nadal, Alicia
  • Olmedo, Verónica
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Challenges associated with biomarker-based classification systems for Alzheimer's disease

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dickerson, Bradford C.
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • de Leon, Mony J..
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
We aimed to evaluate the consistency of the A/T/N classification system. We included healthy controls, mild cognitive impairment, and dementia patients from Alzheimer's disease Neuroimaging Initiative. We assessed subject classification consistency with different biomarker combinations and the agreement and correlation between biomarkers. Subject classification discordance ranged from 12.2% to 44.5% in the whole sample; 17.3%-46.4% in healthy controls; 11.9%-46.5% in mild cognitive impairment, and 1%-35.7% in dementia patients. Amyloid, but not neurodegeneration biomarkers, showed good agreement both in the whole sample and in the clinical subgroups. Amyloid biomarkers were correlated in the whole sample, but not along the Alzheimer's disease continuum (as defined by a positive amyloid positron emission tomography). Neurodegeneration biomarkers were poorly correlated both in the whole sample and along the Alzheimer's disease continuum. The relationship between biomarkers was stage-dependent. Our findings suggest that the current A/T/N classification system does not achieve the required consistency to be used in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Pané, Adriana|||0000-0002-7810-1827
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Ibarzabal, Ainitze|||0000-0002-1220-6474
  • Casajoana, Anna
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • de Hollanda, Ana|||0000-0001-9114-8614
  • Vidal, Josep|||0000-0002-4564-4518
  • Ortega, Emilio|||0000-0002-2217-8905
  • Osorio, Ricardo|||0000-0002-2735-9609
  • Convit, Antonio
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. We selected controls from ADNI2 with CSF AD biomarkers and/or fluorodeoxyglucose positron emission tomography (FDG-PET) and 3T-MRI. We measured cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1-42, p-tau, and t-tau levels. We performed regression analyses between these biomarkers and body mass index (BMI). We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m 2). Higher BMI was related to less cortical thickness and higher metabolism in brain areas typically not involved in AD (family-wise error [FWE] <0.05), but not to AD CSF biomarkers. It is notable that the impact of obesity on brain metabolism and structure was also found in amyloid negative individuals. In the cognitively unimpaired elderly, obesity has differential effects on brain metabolism and structure independent of an underlying AD pathophysiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey

  • Hüls, Anke|||0000-0002-6005-417X
  • Costa, Alberto C. S.
  • Dierssen, Mara|||0000-0003-0853-6865
  • Baksh, Asaad|||0000-0001-6596-2145
  • Bargagna, Stefania
  • Baumer, Nicole
  • Brandão, Ana Claudia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Chicoine, Brian|||0000-0002-1520-3893
  • Ghosh, Sujay
  • Lakhanpaul, Monica
  • Manso, Coral
  • Mayer, Miguel-Angel
  • Ortega, Maria del Carmen
  • de Asua, Diego Real
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Russell, Lauren Ashley
  • Sgandurra, Giuseppina
  • Valentini, Diletta
  • Sherman, Stephanie L.
  • Strydom, Andre
Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0.01), whereas altered consciousness/confusion were more frequent (p < 0.01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3.5 (95%-CI=2.6;4.4), ISARIC4C DS versus non-DS patients: RR = 2.9 (95%-CI=2.1;3.8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Benejam, Bessy|||0000-0002-6789-8615
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Xiao, Mei-Fang
  • Xu, Desheng
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Worley, Paul
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Belbin, Olivia|||0000-0002-6109-6371
There is an urgent need for objective markers of Alzheimer's disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. Previously, GluA4 and neuronal pentraxin 2 (NPTX2) showed limited potential as cerebrospinal fluid (CSF) markers of cognitive impairment in adults with DS. Here, we compare the CSF profile of a panel of synaptic proteins (Calsyntenin-1, Neuroligin-2, Neurexin-2A, Neurexin-3A, Syntaxin-1B, Thy-1, VAMP-2) to that of NPTX2 and GluA4 in a large cohort of subjects with DS across the preclinical and clinical AD continuum and explore their correlation with cognitive impairment. We quantified the synaptic panel proteins by selected reaction monitoring in CSF from 20 non-trisomic cognitively normal controls (mean age 44) and 80 adults with DS grouped according to clinical AD diagnosis (asymptomatic, prodromal AD or AD dementia). We used regression analyses to determine CSF changes across the AD continuum and explored correlations with age, global cognitive performance (CAMCOG), episodic memory (modified cued-recall test; mCRT) and CSF biomarkers, CSF Aβ ratio, CSF Aβ, CSF p-tau, and CSF NFL. P values were adjusted for multiple testing. In adults with DS, VAMP-2 was the only synaptic protein to correlate with episodic memory (delayed recall adj.p =.04) and age (adj.p =.0008) and was the best correlate of CSF Aβ (adj.p =.0001), p-tau (adj.p < .0001), and NFL (adj.p < .0001). Compared to controls, mean VAMP-2 levels were lower in asymptomatic adults with DS only (adj.p =.02). CSF levels of Neurexin-3A, Thy-1, Neurexin-2A, Calysntenin-1, Neuroligin-2, GluA4, and Syntaxin-1B all strongly correlated with NPTX2 (p <.0001), which was the only synaptic protein to show reduced CSF levels in DS at all AD stages compared to controls (adj.p <.002). These data show proof-of-concept for CSF VAMP-2 as a potential marker of synapse degeneration that correlates with CSF AD and axonal degeneration markers and cognitive performance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease, A paired CSF and plasma study

  • Pentz, Rowan
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Ducatenzeiler, Adriana
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Cuello, AC.|||0000-0003-2143-2745
The discovery that nerve growth factor (NGF) metabolism is altered in Down syndrome (DS) and Alzheimer's disease (AD) brains offered a framework for the identification of novel biomarkers signalling NGF deregulation in AD pathology. We examined levels of NGF pathway proteins (proNGF, neuroserpin, tissue plasminogen activator [tPA], and metalloproteases [MMP]) in matched cerebrospinal fluid (CSF)/plasma samples from AD-symptomatic (DSAD) and AD-asymptomatic (aDS) individuals with DS, as well as controls (HC). ProNGF and MMP-3 were elevated while tPA was decreased in plasma from individuals with DS. CSF from individuals with DS showed elevated proNGF, neuroserpin, MMP-3, and MMP-9. ProNGF and MMP-9 in CSF differentiated DSAD from aDS (area under the curve = 0.86, 0.87). NGF pathway markers associated with CSF amyloid beta and tau and differed by sex. Brain NGF metabolism changes can be monitored in plasma and CSF, supporting relevance in AD pathology. These markers could assist staging, subtyping, or precision medicine for AD in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone

  • Estellés, Teresa
  • Zhu, Nuole|||0000-0002-0015-9455
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Subirana, Andrea
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Belbin, Olivia|||0000-0002-6109-6371
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10.1186/s13195-022-00967-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex differences in the behavioral variant of frontotemporal dementia, A new window to executive and behavioral reserve

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Casaletto, Kaitlin B.
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Wolf, Amy
  • Cobigo, Yann|||0000-0002-0354-4092
  • Goh, Sheng Yang M.
  • Staffaroni, Adam M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Brugulat-Serrat, Anna
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Grinberg, Lea T.
  • Possin, Katherine
  • Rankin, Katherine P.
  • Kramer, Joel H.|||0000-0002-2917-8297
  • Rabinovici, Gil D.
  • Boxer, Adam
  • Seeley, William W.
  • Sturm, Virginia E.
  • Gorno-Tempini, Maria Luisa
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Perry, David C.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rosen, Howard J.|||0000-0001-9281-7402
Biological sex is an increasingly recognized factor driving clinical and structural heterogeneity in Alzheimer's disease, but its role in the behavioral variant of frontotemporal dementia (bvFTD) is unknown. We included 216 patients with bvFTD and 235 controls with magnetic resonance imaging (MRI) from a large multicenter cohort. We compared the clinical characteristics and cortical thickness between men and women with bvFTD and controls. We followed the residuals approach to study behavioral and cognitive reserve. At diagnosis, women with bvFTD showed greater atrophy burden in the frontotemporal regions compared to men despite similar clinical characteristics. For a similar amount of atrophy, women demonstrated better-than-expected scores on executive function and fewer changes in apathy, sleep, and appetite than men. Our findings suggest that women might have greater behavioral and executive reserve than men, and neurodegeneration must be more severe in women to produce symptoms similar in severity to those in men.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evaluation of biochemical and hematological parameters in adults with Down syndrome

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garzón, Diana
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Fortea, Juan|||0000-0002-1340-638X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
Down syndrome (DS) is the most common worldwide cause of intellectual disability of genetic origin and the most common chromosomal disorder affecting live-born infants. In addition to intellectual disability, individuals with DS have other comorbidities and complex medical conditions. The increase in the life expectancy of patients with DS requires expanding the knowledge about their clinical characteristics and related laboratory parameters. Several studies exploring laboratory tests in DS patients exist, but their focus is limited to specific areas of metabolism. Therefore, our main goal was to describe the biochemical and hematological findings in a DS cohort and to compare the values to those of a control population. A total of 248 DS individuals and 84 control subjects were enrolled. DS individuals had a higher frequency of several clinical conditions compared to control individuals and presented with significant differences with respect to the controls in both biochemical and hematological parameters. We found age- and sex-related differences in several of the parameters. A good understanding of the differences in our cohort might be of aid in the clinical follow-up of adults with DS, especially considering that the lifespan of DS individuals may reach 60 years of age in developed countries.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders

  • Ramírez, Sara
  • Haddad-Tóvolli, Roberta
  • Radosevic, Marija
  • Toledo, Miriam
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Ribas Ripoll, Vicent|||0000-0002-7266-6106
  • Milà-Guasch, Maria
  • Pozo, Macarena
  • Obri, Arnaud
  • Eyre Sánchez, Elena
  • Gómez-Valadés, Alicia G.
  • Chivite, Iñigo
  • Van Eeckhout, Tomas
  • Zalachoras, Ioannis
  • Altirriba, Jordi
  • Bauder, Corinna
  • Imbernón, Mónica
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Garcia-Ruiz, Carmen
  • Nogueiras, Rubén|||0000-0002-9976-9930
  • Soto, David
  • Gasull, Xavier|||0000-0002-6154-8323
  • Sandi, Carmen|||0000-0001-7713-8321
  • Brüning, Jens C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Fernández-Checa, José C.
  • Claret, Marc
Obesity and type 2 diabetes are associated with cognitive dysfunction. Because the hypothalamus is implicated in energy balance control and memory disorders, we hypothesized that specific neurons in this brain region are at the interface of metabolism and cognition. Acute obesogenic diet administration in mice impaired recognition memory due to defective production of the neurosteroid precursor pregnenolone in the hypothalamus. Genetic interference with pregnenolone synthesis by Star deletion in hypothalamic POMC, but not AgRP neurons, deteriorated recognition memory independently of metabolic disturbances. Our data suggest that pregnenolone's effects on cognitive function were mediated via an autocrine mechanism on POMC neurons, influencing hippocampal long-term potentiation. The relevance of central pregnenolone on cognition was also confirmed in metabolically unhealthy patients with obesity. Our data reveal an unsuspected role for POMC neuron-derived neurosteroids in cognition. These results provide the basis for a framework to investigate new facets of POMC neuron biology with implications for cognitive disorders. Ramírez et al. show that reduced hypothalamic pregnenolone levels, in the context of metabolic diseases, are associated with cognitive deterioration. POMC neuron-derived pregnenolone is a key mediator of cognition, but not metabolism, acting via hippocampal mechanisms. These results identify an unsuspected role for POMC neuron-derived pregnenolone in memory performance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AMYQ, An index to standardize quantitative amyloid load across PET tracers

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Aranha, Mateus|||0000-0001-9594-292X
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carrió, Ignasi|||0000-0003-1135-5352
  • Camacho, Valle|||0000-0003-0748-0847
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Positron emission tomography (PET) amyloid quantification methods require magnetic resonance imaging (MRI) for spatial registration and a priori reference region to scale the images. Furthermore, different tracers have distinct thresholds for positivity. We propose the AMYQ index, a new measure of amyloid burden, to overcome these limitations. We selected 18F-amyloid scans from ADNI and Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) with the corresponding T1-MRI. A subset also had neuropathological data. PET images were normalized, and the AMYQ was calculated based on an adaptive template. We compared AMYQ with the Centiloid scale on clinical and neuropathological diagnostic performance. AMYQ was related with amyloid neuropathological burden and had excellent diagnostic performance to discriminate controls from patients with Alzheimer's disease (AD) (area under the curve [AUC] = 0.86). AMYQ had a high agreement with the Centiloid scale (intraclass correlation coefficient [ICC] = 0.88) and AUC between 0.94 and 0.99 to discriminate PET positivity when using different Centiloid cutoffs. AMYQ is a new MRI-independent index for standardizing and quantifying amyloid load across tracers.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Epilepsy in Down Syndrome, A Highly Prevalent Comorbidity

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Giménez, Sandra|||0000-0001-8031-2319
  • Fortea, Juan|||0000-0002-1340-638X
Individuals with Down syndrome (DS) have an increased risk for epilepsy during the whole lifespan, but especially after age 40 years. The increase in the number of individuals with DS living into late middle age due to improved health care is resulting in an increase in epilepsy prevalence in this population. However, these epileptic seizures are probably underdiagnosed and inadequately treated. This late onset epilepsy is linked to the development of symptomatic Alzheimer's disease (AD), which is the main comorbidity in adults with DS with a cumulative incidence of more than 90% of adults by the seventh decade. More than 50% of patients with DS and AD dementia will most likely develop epilepsy, which in this context has a specific clinical presentation in the form of generalized myoclonic epilepsy. This epilepsy, named late onset myoclonic epilepsy (LOMEDS) affects the quality of life, might be associated with worse cognitive and functional outcomes in patients with AD dementia and has an impact on mortality. This review aims to summarize the current knowledge about the clinical and electrophysiological characteristics, diagnosis and treatment of epileptic seizures in the DS population, with a special emphasis on LOMEDS. Raised awareness and a better understanding of epilepsy in DS from families, caregivers and clinicians could enable earlier diagnoses and better treatments for individuals with DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Montal, Victor|||0000-0002-5714-9282
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, Susana|||0000-0002-9777-1156
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Garzón, Diana
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Camacho, Valle|||0000-0003-0748-0847
  • Medrano-Martorell, Santiago|||0000-0002-6586-7284
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Blennow, Kaj|||0000-0002-1890-4193
  • Fortea, Juan|||0000-0002-1340-638X
  • Zetterberg, Henrik|||0000-0003-3930-4354
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS. Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease

  • Giménez, Sandra|||0000-0001-8031-2319
  • Farre, Ariadna
  • Morente, Fátima
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Gutiérrez, Marta
  • Clos, Susana|||0000-0001-5350-821X
  • Fernández-Arcos, Ana
  • Blanco, Marta
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Asensio, Amparo
  • Benejam, Bessy|||0000-0002-6789-8615
  • Batista, Mar
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fortuna Gutiérrez, Ana Mª|||0000-0002-3619-1609
  • Fortea, Juan|||0000-0002-1340-638X
  • Mayos, Merce|||0000-0003-3972-3671
.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome

  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernandez, S.
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Muñoz, Laia|||0000-0003-0578-3094
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Camacho, Valle|||0000-0003-0748-0847
  • Wilson, Liam Reese
  • Annus, Tiina
  • Osorio, R.S.
  • Videla, S.
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony|||0000-0003-4107-130X
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. Objective: To investigate the association of the APOE ϵ4 allele with clinical and multimodal biomarkers of AD in adults with DS. Design, Setting, and Participants: This dual-center cohort study recruited adults with DS in Barcelona, Spain, and in Cambridge, UK, between June 1, 2009, and February 28, 2020. Included individuals had been genotyped for APOE and had at least 1 clinical or AD biomarker measurement; 2 individuals were excluded because of the absence of trisomy 21. Participants were either APOE ϵ4 allele carriers or noncarriers. Main Outcomes and Measures: Participants underwent a neurological and neuropsychological assessment. A subset of participants had biomarker measurements: Aβ1-42, Aβ1-40, phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) in cerebrospinal fluid (CSF), pTau181, and NfL in plasma; amyloid positron emission tomography (PET); fluorine 18-labeled-fluorodeoxyglucose PET; and/or magnetic resonance imaging. Age at symptom onset was compared between APOE ϵ4 allele carriers and noncarriers, and within-group local regression models were used to compare the association of biomarkers with age. Voxelwise analyses were performed to assess topographical differences in gray matter metabolism and volume. Results: Of the 464 adults with DS included in the study, 97 (20.9%) were APOE ϵ4 allele carriers and 367 (79.1%) were noncarriers. No differences between the 2 groups were found by age (median [interquartile range], 45.9 [36.4-50.2] years vs 43.7 [34.9-50.2] years; P =.56) or sex (51 male carriers [52.6%] vs 199 male noncarriers [54.2%]). APOE ϵ4 allele carriers compared with noncarriers presented with AD symptoms at a younger age (mean [SD] age, 50.7 [4.4] years vs 52.7 [5.8] years; P =.02) and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by nonoverlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ϵ4 allele carriers. Conclusions and Relevance: In this study, the APOE ϵ4 allele was associated with earlier clinical and biomarker changes of AD in DS. These results provide insights into the mechanisms by which APOE increases the risk of AD, emphasizing the importance of APOE genotype for future clinical trials in DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Sleep disorders in adults with down syndrome

  • Giménez, Sandra|||0000-0001-8031-2319
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Blessing, Esther
  • Osorio, Ricardo M.
  • Fortea, Juan|||0000-0002-1340-638X
Sleep disorders, despite being very frequent in adults with Down syndrome (DS), are often overlooked due to a lack of awareness by families and physicians and the absence of specific clinical sleep guidelines. Untreated sleep disorders have a negative impact on physical and mental health, behavior, and cognitive performance. Growing evidence suggests that sleep disruption may also accelerate the progression to symptomatic Alzheimer's disease (AD) in this population. It is therefore imperative to have a better understanding of the sleep disorders associated with DS in order to treat them, and in doing so, improve cognition and quality of life, and prevent related comorbidities. This paper reviews the current knowledge of the main sleep disorders in adults with DS, including evaluation and management. It highlights the existing gaps in knowledge and discusses future directions to achieve earlier diagnosis and better treatment of sleep disorders most frequently found in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation

  • Tost, Josep|||0000-0003-3846-9616
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Cotter, Gad|||0000-0002-9613-3339
  • Davison, Beth A.
  • Jacob, Javier|||0000-0003-1101-1066
  • Gil, Víctor
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
  • Martín-Sánchez, Francisco Javier|||0000-0002-5970-725X
  • Donea, Ruxandra
  • Rodríguez, Beatriz|||0000-0002-0402-3838
  • Lucas-Imbernon, Francisco Javier
  • Andueza, Juan Antonio
  • Mecina, Ana Belén
  • Torres Gárate, Raquel|||0000-0002-8731-9350
  • Piñera, Pascual|||0000-0001-9213-9357
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Espinosa, Bego|||0000-0001-9531-6451
  • Mebazaa, A.
  • Chioncel, O.|||0000-0002-3197-3628
  • Miró, Oscar|||0000-0002-7924-9751
Aims: To analyze the frequency with which patients with heart failure with preserved ejection fraction (HFpEF) discharged after an acute heart failure (AHF) episode are treated with antineurohormonal drugs (ANHD), the variables related to ANHD prescription and their relationship with outcomes. Methods: We included consecutive HFpEF patients (left ventricular ejection fraction ≥50%) discharged after an AHF episode from 45 Spanish hospitals whose chronic medications and treatment at discharge were available. Patients were classified according to whether they were discharged with or without ANHD, including beta-blockers (BB), renin-angiotensin-aldosterone-system inhibitors (RAASi) and mineralcorticosteroid-receptor antagonists (MRA). Co-primary outcomes consisted of 1-year all-cause mortality and 90-day combined adverse event (revisit to emergency department -ED-, hospitalization due to AHF or all-cause death). Secondary outcomes were 90-day adverse events taken individually. Adjusted associations of ANHD treatment with outcomes were calculated. Results: We analyzed 3,305 patients with HFpEF (median age: 83, 60% women), 2,312 (70%) discharged with ANHD. The ANHD most frequently prescribed was BB (45.8%). The 1-year mortality was 26.9% (adjusted HR for ANHD patients:1.17, 95%CI=0.98-1.38) and the 90-day combined adverse event was 54.4% (HR=1.14, 95%CI=0.99-1.31). ED revisit was significantly increased by ANHD (HR=1.15, 95%CI=1.01-1.32). MRA and BB were associated with worse results in some co-primary or secondary endpoints, while RAASi (alone) reduced 90-day hospitalization (HR=0.73, 98%CI=0.56-0.96). Conclusion: 70% of HFpEF patients are discharged with ANHD after an AHF episode. ANHD do not seem to reduce mortality or adverse events in HFpEF patients, only RAASi could provide some benefits, reducing the risk of hospitalization for AHF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early intravenous nitroglycerin use in prehospital setting and in the emergency department to treat patients with acute heart failure, Insights from the EAHFE Spanish registry

  • Miró, Oscar|||0000-0002-7924-9751
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Freund, Yonathan
  • Davison, Beth A.
  • Takagi, Koji
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
  • Jacob, Javier|||0000-0003-1101-1066
  • Martín-Sánchez, Francisco Javier|||0000-0002-5970-725X
  • Gil, Víctor
  • Rossello, Xavier|||0000-0001-6783-8463
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Jiménez-Fábrega, Francesc X.
  • Masip, Josep|||0000-0002-8612-9889
  • Mebazaa, Alexandre|||0000-0001-8715-7753
  • Cotter, Gad|||0000-0002-9613-3339
Background and objective: Although recommended for the treatment of acute heart failure (AHF), the use of intravenous (IV) nitroglycerin (NTG) is supported by scarce and contradicting evidence. In the current analysis, we have assessed the impact of IV NTG administration by EMS or in emergency department (ED) on outcomes of AHF patients. Methods: We analyze AHF patients included by 45 hospitals that were delivered to ED by EMS. Patients were grouped according to whether treatment with IV NTG was started by EMS before ED admission (preED-NTG), during the ED stay (ED-NTG) or were untreated with IV NTG (no-NTG, control group). In-hospital, 30-day and 365-day all-cause mortality, prolonged hospitalization (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  • Solana, Elisabeth|||0000-0001-7973-2439
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Lopez-Soley, Elisabet
  • Radua, Joaquim|||0000-0003-1240-5438
  • Sola-Valls, Nuria
  • Montejo, Carmen
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Pulido-Valdeolivas, Irene|||0000-0003-0188-2458
  • Sepúlveda, Maria
  • Andorra, Magí
  • Berenguer, Juan|||0000-0001-8541-8200
  • Villoslada, P.|||0000-0002-8735-6119
  • Martinez-Lapiscina, E.H.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Saiz, Albert|||0000-0002-5793-8791
  • Fortea, Juan|||0000-0002-1340-638X
  • Llufriu, Sara|||0000-0003-4273-9121
The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer's disease

  • Rujeedawa, Tanzil|||0000-0002-7089-1684
  • Carrillo Félez, Eva
  • Clare, Isabel C.H.|||0000-0002-5385-008X
  • Fortea, Juan|||0000-0002-1340-638X
  • Strydom, Andre
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Coppus, Antonia
  • Levin, Johannes|||0000-0001-5092-4306
  • Zaman, Shahid
The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's disease in (DSAD) and Autosomal Dominant Alzheimer's disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Behavioral and Psychological Symptoms of Dementia in down Syndrome Scale (BPSD-DS II), Optimization and Further Validation

  • Dekker, Alain D.|||0000-0001-8771-218X
  • Ulgiati, Aurora M.|||0000-0001-6393-946X
  • Groen, Henk|||0000-0002-6629-318X
  • Boxelaar, Vicent A.
  • Sacco, Silvia
  • Falquero, Ségolène
  • Carfi, Angelo|||0000-0002-9837-7003
  • Di Paola, Antonella
  • Benejam, Bessy|||0000-0002-6789-8615
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fopma, Roelie
  • Oosterik, Marjo
  • Hermelink, Marloes
  • Beugelsdijk, Gonny
  • Schippers, Mieke
  • Henstra, Hepie
  • Scholten-Kuiper, Martine
  • Willink-Vos, Judith
  • De Ruiter, Lisa
  • Willems, Liesbeth
  • Loonstra-De Jong, Anneke
  • Coppus, Antonia
  • Tollenaere, Marleen
  • Fortea, Juan|||0000-0002-1340-638X
  • Onder, Graziano
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Van Dam, Debby
  • De Deyn, Peter Paul|||0000-0002-2228-2964
Background: People with Down syndrome (DS) are at high risk to develop Alzheimer's disease dementia (AD). Behavioral and psychological symptoms of dementia (BPSD) are common and may also serve as early signals for dementia. However, comprehensive evaluation scales for BPSD, adapted to DS, are lacking. Therefore, we previously developed the BPSD-DS scale to identify behavioral changes between the last six months and pre-existing life-long characteristic behavior. Objective: To optimize and further study the scale (discriminative ability and reliability) in a large representative DS study population. Methods: Optimization was based on item irrelevance and clinical experiences obtained in the initial study. Using the shortened and refined BPSD-DS II, informant interviews were conducted to evaluate 524 individuals with DS grouped according to dementia status: no dementia (DS, N = 292), questionable dementia (DS + Q, N = 119), and clinically diagnosed dementia (DS + AD, N = 113). Results: Comparing item change scores between groups revealed prominent changes in frequency and severity for anxious, sleep-related, irritable, restless/stereotypic, apathetic, depressive, and eating/drinking behavior. For most items, the proportion of individuals displaying an increased frequency was highest in DS + AD, intermediate in DS + Q, and lowest in DS. For various items within sections about anxious, sleep-related, irritable, apathetic, and depressive behaviors, the proportion of individuals showing an increased frequency was already substantial in DS + Q, suggesting that these changes may serve as early signals of AD in DS. Reliability data were promising. Conclusion: The optimized scale yields largely similar results as obtained with the initial version. Systematically evaluating BPSD in DS may increase understanding of changes among caregivers and (timely) adaptation of care/treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neural correlates of episodic memory in adults with Down syndrome and Alzheimer's disease

  • Benejam, Bessy|||0000-0002-6789-8615
  • Aranha, Mateus|||0000-0001-9594-292X
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Padilla, Concepción|||0000-0003-4102-6787
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Videla, Sebastián|||0000-0001-5049-1379
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Background: Adults with Down syndrome are at an ultra-high risk of developing early-onset Alzheimer's disease. Episodic memory deficits are one of the earliest signs of the disease, but their association with regional brain atrophy in the population with Down syndrome has not been explored. We aimed to investigate the neuroanatomical correlates of episodic memory in adults with Down syndrome and symptomatic Alzheimer's disease. Methods: Single-center, cross-sectional study. A total of 139 adults with Down syndrome (85 asymptomatic and 54 with symptomatic Alzheimer's disease) were included in the study (mean age 43.6 ± 10.9 years, 46% female). Episodic memory was assessed using the modified Cued Recall Test. Immediate (trial 1 free immediate recall, trial 3 free immediate recall, total free immediate recall score, and total immediate score) and delayed scores (free delayed recall score and total delayed score) were examined. Cortical thickness from magnetic resonance imaging was determined with surface-based morphometry using the FreeSurfer 6.0 software package. The clusters of reduced cortical thickness were compared between symptomatic and asymptomatic participants to create a cortical atrophy map. Then, the correlation between cortical thickness and the modified Cued Recall Test subscores were separately assessed in symptomatic and asymptomatic subjects, controlling for age, sex, and severity of intellectual disability. Results: Compared with asymptomatic participants, those with symptomatic Alzheimer's disease showed a pattern of cortical atrophy in posterior parieto-temporo-occipital cortices. In symptomatic subjects, trial 1 immediate free recall significantly correlated with cortical atrophy in lateral prefrontal regions. Trial 3 free immediate recall and total free immediate recall were associated with the most widespread cortical atrophy. Total immediate score was related to posterior cortical atrophy, including lateral parietal and temporal cortex, posterior cingulate cortex, precuneus, and medial temporal lobe areas. Delayed memory scores were associated with cortical atrophy in temporoparietal and medial temporal lobe regions. No significant relationships were observed between episodic memory measures and cortical atrophy in asymptomatic subjects. Conclusions: Different episodic memory measures were associated with cortical atrophy in specific brain regions in adults with Down syndrome and Alzheimer's disease. These results overlap with those described in sporadic Alzheimer's disease and further support the similarities between Down syndrome-associated Alzheimer's disease and that in the general population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pronóstico de la insuficiencia cardíaca aguda basado en datos clínicos de congestión, Prognosis of acute heart failure based on clinical data of congestion

  • Espinosa, Bego|||0000-0001-9531-6451
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Gil, V.
  • Rossello, X.
  • Jacob, Javier|||0000-0003-1101-1066
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
  • Martín-Sánchez, Francisco Javier|||0000-0002-5970-725X
  • Alquézar-Arbé, A.|||0000-0003-4164-274X
  • Masip, J.
  • Miró, None
Antecedentes y objetivos: Evaluar si los síntomas/signos de congestión en pacientes con insuficiencia cardíaca aguda (ICA) atendidos en los servicios de urgencias hospitalarios (SUH) permiten predecir la evolución a corto plazo. Pacientes y métodos: Pacientes consecutivos diagnosticados de ICA en 45 SUH del registro EAHFE. Recogimos variables clínicas de congestión sistémica (edemas en miembros inferiores, ingurgitación yugular, hepatomegalia) y pulmonar (disnea de esfuerzo, disnea paroxística nocturna, ortopnea y crepitantes pulmonares) analizando su asociación con la mortalidad por cualquier causa a 30 días, de forma cruda y ajustada por diferencias entre grupos. Resultados: Analizamos 18.120 pacientes (mediana = 83 años, rango intercuartil [RIC] = 76-88; mujeres = 55,7%). El 44,6% presentaba., Background and objectives: This work aims to assess whether symptoms/signs of congestion in patients with acute heart failure (AHF) evaluated in hospital emergency departments (HED) allows for predicting short-term progress. Patients and methods: The study group comprised consecutive patients diagnosed with AHF in 45 HED from EAHFE Registry. We collected clinical variables of systemic congestion (edema in the lower extremities, jugular vein distention, hepatomegaly) and pulmonary congestion (dyspnea on exertion, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary crackles) and analyzed their individual and group association with all-cause 30-day of mortality crudely and adjusted for differences between groups. Results: We analyzed 18,120 patients (median=83 years, interquartile range [IQR]=76-88; women=55.7%). Of them, 44.6% had.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients

  • Moreau, Manon
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Dalzon, Lorraine
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Vilaire, Marie|||0000-0003-4401-7755
  • Durand, Sophie
  • Fortea, Juan|||0000-0002-1340-638X
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Janel, Nathalie
Down syndrome (DS) is a complex genetic condition due to an additional copy of human chromosome 21, which results in the deregulation of many genes. In addition to the intellectual disability associated with DS, adults with DS also have an ultrahigh risk of developing early onset Alzheimer's disease dementia. DYRK1A, a proline-directed serine/threonine kinase, whose gene is located on chromosome 21, has recently emerged as a promising plasma biomarker in patients with sporadic Alzheimer's disease (AD). The protein DYRK1A is truncated in symptomatic AD, the increased truncated form being associated with a decrease in the level of full-length form. Activity-dependent neuroprotective protein (ADNP), a key protein for the brain development, has been demonstrated to be a useful marker for symptomatic AD and disease progression. In this study, we evaluated DYRK1A and ADNP in CSF and plasma of adults with DS and explored the relationship between these proteins. We used mice models to evaluate the effect of DYRK1A overexpression on ADNP levels and then performed a dual-center cross-sectional human study in adults with DS in Barcelona (Spain) and Paris (France). Both cohorts included adults with DS at different stages of the continuum of AD: asymptomatic AD (aDS), prodromal AD (pDS), and AD dementia (dDS). Non-trisomic controls and patients with sporadic AD dementia were included for comparison. Full-form levels of DYRK1A were decreased in plasma and CSF in adults with DS and symptomatic AD (pDS and dDS) compared to aDS, and in patients with sporadic AD compared to controls. On the contrary, the truncated form of DYRK1A was found to increase both in CSF and plasma in adults with DS and symptomatic AD and in patients with sporadic AD with respect to aDS and controls. ADNP levels showed a more complex structure. ADNP levels increased in aDS groups vs. controls, in agreement with the increase in levels found in the brains of mice overexpressing DYRK1A. However, symptomatic individuals had lower levels than aDS individuals. Our results show that the comparison between full-length and truncated-form levels of DYRK1A coupled with ADNP levels could be used in trials targeting pathophysiological mechanisms of dementia in individuals with DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome

  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Fernández, Susana|||0000-0002-9777-1156
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Giménez, Sandra|||0000-0001-8031-2319
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • El Bounasri El Bennadi, Shaimaa|||0000-0003-1580-9649
  • Padilla, Concepción|||0000-0003-4102-6787
  • Aranha, Mateus|||0000-0001-9594-292X
  • Estellés, Teresa
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Belbin, Olivia|||0000-0002-6109-6371
  • Valle-Tamayo, Natalia|||0000-0001-9322-3710
  • Camacho, Valle|||0000-0003-0748-0847
  • Blessing, Esther
  • Osorio, Ricardo S.
  • Videla, Sebastián|||0000-0001-5049-1379
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Holland, Anthony J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Zaman, Shahid
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
The study of sex differences in Alzheimer's disease is increasingly recognized as a key priority in research and clinical development. People with Down syndrome represent the largest population with a genetic link to Alzheimer's disease (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Correction, Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD. The online version contains supplementary material available at 10.1186/s40035-021-00275-w.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Nigro, Salvatore
  • Vandevrede, Lawren
  • Falgàs, Neus|||0000-0002-3404-2765
  • Heuer, Hilary W.
  • Painous, Cèlia|||0000-0002-7027-3093
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Montal, Victor|||0000-0002-5714-9282
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Quattrone, Andrea
  • Perry, David C.
  • Gorno-Tempini, Maria Luisa
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Grinberg, Lea T.
  • Spina, Salvatore
  • La Joie, Renaud
  • Rabinovici, Gil D.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Rojas, Julio C.|||0000-0002-1308-646X
  • Seeley, William W.
  • Boxer, Adam
Importance: The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective: To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants: This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures: The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results: Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance: In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microstructure in primary progressive aphasia, a multicenter study

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Mandelli, Maria Luisa|||0000-0002-2518-2520
  • Falgàs, Neus|||0000-0002-3404-2765
  • Welch, Ariane E.
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Blesa, Rafael|||0000-0003-4026-2884
  • Dickerson, Bradford C.
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gorno-Tempini, Maria Luisa
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients

  • Lennol, Matthew Paul
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Cuchillo-Ibáñez, Inmaculada|||0000-0002-3689-5518
  • Camporesi, Elena
  • Brinkmalm, Gunnar
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Soria, Guadalupe
  • Aguado, Fernando|||0000-0002-0393-1308
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Blennow, Kaj|||0000-0002-1890-4193
  • Sáez-Valero, Javier
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer's disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with down syndrome

  • Belbin, Olivia|||0000-0002-6109-6371
  • Xiao, M.F.
  • Xu, D.
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, S.
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Worley, P.F.
  • Fortea, Juan|||0000-0002-1340-638X
Alzheimer's disease (AD) is the major cause of death in adults with Down syndrome (DS). There is an urgent need for objective markers of AD in the DS population to improve early diagnosis and monitor disease progression. NPTX2 has recently emerged as a promising cerebrospinal fluid (CSF) biomarker of Alzheimer-related inhibitory circuit dysfunction in sporadic AD patients. The objective of this study was to evaluate NPTX2 in the CSF of adults with DS and to explore the relationship of NPTX2 to CSF levels of the PV interneuron receptor, GluA4, and existing AD biomarkers (CSF and neuroimaging). This is a cross-sectional, retrospective study of adults with DS with asymptomatic AD (aDS, n = 49), prodromal AD (pDS, n = 18) and AD dementia (dDS, n = 27). Non-trisomic controls (n = 34) and patients with sporadic AD dementia (sAD, n = 40) were included for comparison. We compared group differences in CSF NPTX2 according to clinical diagnosis and degree of intellectual disability. We determined the relationship of CSF NPTX2 levels to age, cognitive performance (CAMCOG, free and cued selective reminding, semantic verbal fluency), CSF levels of a PV-interneuron marker (GluA4) and core AD biomarkers; CSF Aβ1-42, CSF t-tau, cortical atrophy (magnetic resonance imaging) and glucose metabolism ([18F]-fluorodeoxyglucose positron emission tomography). Compared to controls, mean CSF NPTX2 levels were lower in DS at all AD stages; aDS (0.6-fold, adj.p < 0.0001), pDS (0.5-fold, adj.p < 0.0001) and dDS (0.3-fold, adj.p < 0.0001). This reduction was similar to that observed in sporadic AD (0.5-fold, adj.p < 0.0001). CSF NPTX2 levels were not associated with age (p = 0.6), intellectual disability (p = 0.7) or cognitive performance (all p.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests

  • Benejam, Bessy|||0000-0002-6789-8615
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Fernandez, S.
  • Giménez, Sandra|||0000-0001-8031-2319
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Garzón, Diana
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Bartrés-Faz, David|||0000-0001-6020-4118
  • Videla, S.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
We aimed to define prodromal Alzheimer's disease (AD) and AD dementia using normative neuropsychological data in a large population-based cohort of adults with Down syndrome (DS). Cross-sectional study. DS participants were classified into asymptomatic, prodromal AD and AD dementia, based on neurologist's judgment blinded to neuropsychological data (Cambridge Cognitive Examination for Older Adults with Down's syndrome [CAMCOG-DS] and modified Cued Recall Test [mCRT]). We compared the cutoffs derived from the normative data in young adults with DS to those from receiver-operating characteristic curve (ROC) analysis. Diagnostic performance of the CAMCOG-DS and modified Cued Recall Test (mCRT) in subjects with mild and moderate levels of intellectual disability (ID) was high, both for diagnosing prodromal AD and AD dementia (area under the curve [AUC] 0.73-0.83 and 0.90-1, respectively). The cutoffs derived from the normative data were similar to those derived from the ROC analyses. Diagnosing prodromal AD and AD dementia in DS with mild and moderate ID using population norms for neuropsychological tests is possible with high diagnostic accuracy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study

  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Casajoana, Anna
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Ortega, Emilio|||0000-0002-2217-8905
  • Vidal, Josep|||0000-0002-4564-4518
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
Mid-life obesity is an established risk factor for Alzheimer's disease (AD) dementia,whereas late-life obesity has been proposed as a protective state. Weight loss, whichpredates cognitive decline, might explain this obesity paradox on AD risk. We aimedto assess the impact of late life obesity on brain structure taking into account weightloss as a potential confounder. We included 162 elderly controls of the Alzheimer'sDisease Neuroimaging Initiative (ADNI) with available 3T MRI scan. Significant weightloss was defined as relative weight loss =5% between the baseline and last followup visit. To be able to capture weight loss, only subjects with a minimum clinical andanthropometrical follow-up of 12 months were included. Individuals were categorizedinto three groups according to body mass index (BMI) at baseline: normal-weight(BMI<25 Kg/m), overweight (BMI 25-30 Kg/m) and obese (BMI.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Alzheimer's disease research progress in the Mediterranean region, The Alzheimer's Association International Conference Satellite Symposium

  • Sexton, Claire|||0000-0002-3846-2986
  • Solis, Michele
  • Aharon-Peretz, Judith
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Apostolova, Liana G.
  • Bayen, Eléonore
  • Birkenhager, Betty
  • Cappa, Stefano
  • Constantinidou, Fofi|||0000-0002-7928-8363
  • Fortea, Juan|||0000-0002-1340-638X
  • Gerritsen, Debby L.
  • Hassanin, Hany I.
  • Ibáñez, Agustín|||0000-0001-6758-5101
  • Ioannidis, Panagiotis|||0000-0003-0254-6624
  • Karageorgiou, Elissaios
  • Korczyn, Amos
  • Leroi, Iracema
  • Lichtwarck, Bjorn
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Lynch, Chris
  • Mecocci, Patrizia|||0000-0003-0729-5246
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Papatriantafyllou, John
  • Papegeorgiou, Sokratis
  • Politis, Antonis
  • Raman, Rema
  • Ritchie, Karen
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Sano, Mary
  • Scarmeas, Nikolas
  • Spiru, Luiza
  • Stathi, Afroditi
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Yener, Gorsev|||0000-0002-7756-4387
  • Zaganas, Ioannis|||0000-0002-0774-5772
  • Zygouris, Stelios|||0000-0001-9384-1826
  • Carrillo, Maria|||0000-0003-3057-2387
As research and services in the Mediterranean region continue to increase, so do opportunities for global collaboration. To support such collaborations, the Alzheimer's Association was due to hold its seventh Alzheimer's Association International Conference Satellite Symposium in Athens, Greece in 2021. Due to the COVID-19 pandemic, the meeting was held virtually, which enabled attendees from around the world to hear about research efforts in Greece and the surrounding Mediterranean countries. Research updates spanned understanding the biology of, treatments for, and care of people with Alzheimer's disease (AD_ and other dementias. Researchers in the Mediterranean region have outlined the local epidemiology of AD and dementia, and have identified regional populations that may expedite genetic studies. Development of biomarkers is expected to aid early and accurate diagnosis. Numerous efforts have been made to develop culturally specific interventions to both reduce risk of dementia, and to improve quality of life for people living with dementia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

  • Guillén, Núria|||0000-0002-1341-9834
  • Contador, José
  • Buongiorno, Mariateresa
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Culell, Natalia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Piñol-Ripoll, Gerard
  • Carnes-Vendrell, Anna
  • Ispierto, María Lourdes|||0000-0002-1837-9675
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Balasa, Mircea|||0000-0002-1795-4228
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta (Aβ, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ/Aβ (n = 155), 88% for pTau181/Aβ (n = 94) and 82% for tTau/Aβ (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ/Aβ was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid

  • Gagliardi, Geoffroy|||0000-0002-2608-8456
  • Montal, Victor|||0000-0002-5714-9282
  • Sepulcre, Jorge|||0000-0002-4199-2304
  • Diez, Ibai
  • Lois, Cristina|||0000-0002-8766-2212
  • Hanseeuw, Bernard
  • Schultz, Aaron P.
  • Properzi, Michael J.
  • Papp, Kathryn V.
  • Marshall, Gad A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Johnson, Keith A.
  • Sperling, Reisa|||0000-0003-1535-6133
  • Vannini, Patrizia|||0000-0002-9425-1059
  • Rodriguez-Vieitez, Elena|||0000-0002-6639-8141
Non-invasive diffusion-weighted imaging (DWI) to assess brain microstructural changes via cortical mean diffusivity (cMD) has been shown to be cross-sectionally associated with tau in cognitively normal older adults, suggesting that it might be an early marker of neuronal injury. Here, we investigated how regional cortical microstructural changes measured by cMD are related to the longitudinal accumulation of regional tau as well as to episodic memory decline in cognitively normal individuals harboring amyloid pathology. 122 cognitively normal participants from the Harvard Aging Brain Study underwent DWI, T1w-MRI, amyloid and tau PET imaging, and Logical Memory Delayed Recall (LMDR) assessments. We assessed whether the interaction of baseline amyloid status and cMD (in entorhinal and inferior-temporal cortices) was associated with longitudinal regional tau accumulation and with longitudinal LMDR using separate linear mixed-effects models. We find a significant interaction effect of the amyloid status and baseline cMD in predicting longitudinal tau in the entorhinal cortex (p = 0.044) but not the inferior temporal lobe, such that greater baseline cMD values predicts the accumulation of entorhinal tau in amyloid-positive participants. Moreover, we find a significant interaction effect of the amyloid status and baseline cMD in the entorhinal cortex (but not inferior temporal cMD) in predicting longitudinal LMDR (p < 0.001), such that baseline entorhinal cMD predicts the episodic memory decline in amyloid-positive participants. The combination of amyloidosis and elevated cMD in the entorhinal cortex may help identify individuals at short-term risk of tau accumulation and Alzheimer's Disease-related episodic memory decline, suggesting utility in clinical trials.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

ESR Essentials: diffusion-weighted MRI—practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology

  • Palombo, Marco
  • Tang, Guoheng
  • Le Bihan, Denis
  • Nilsson, Markus
  • Grussu, Francesco
  • Perez-Lopez, Raquel
Diffusion magnetic resonance imaging; Human body; Human brain, Resonancia magnética de difusión; Cuerpo humano; Cerebro humano, Ressonància magnètica de difusió; Cos humà; Cervell humà, Diffusion-weighted imaging (DWI) offers critical insights into tissue microstructure through the assessment of water molecule random displacements and plays a central role in the assessment of neoplastic and non-neoplastic diseases. To successfully implement and use DWI in clinical practice, guidelines for acquisition, interpretation of image contrast and of artefacts should be followed, taking the disease process and body part into account. We recommend covering a b-value range of 0–1000 s/mm2 in the brain (along at least six directions for white matter), and 50–800 s/mm2 in the body. Available acquisition acceleration options should be used to reduce repetition time (TR), echo time (TE), and echo-planar imaging (EPI) distortions, while considering the penalty in signal-to-noise ratio (SNR) and image sharpness. DW images and the apparent diffusion coefficient (ADC) map should be read jointly for the clinical interpretation. Areas of slower diffusion are hyperintense on DW images and hypointense on the ADC map, and vice versa. Magnetic susceptibility distortions and signal drop-outs or pile-ups are particularly pronounced at air-tissue or metal-tissue interfaces and may obscure areas of interest or hinder the co-localisation with structural scans. By following these guidelines and recommendations, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications. Key Points This article provides an overview of DWI principles, clinical applications, potential pitfalls, and emerging advances, alongside expert recommendations for optimal implementation. We provide key considerations tailored to specific applications (neuro and whole-body imaging), including protocol optimisation, adherence to established guidelines, and quality assurance measures to minimise artefacts and ensure reproducibility. By following the guidelines and recommendations summarised in this work, radiologists and imaging professionals can enhance diagnostic accuracy, reduce variability, and maximise the clinical value of DWI across diverse applications., The authors state that this work has not received any funding. M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2 and the Medical Research Council research grant MR/W031566/1. R.P.-L. is supported by ‘la Caixa’ Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). F.G. receives the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”. I.O.J. is supported by the SNSF Eccellenza fellowship #194260. M.N. is supported by the Swedish Cancer Foundation (FO2024-0335-HK-73) and the Swedish Science Council (2024-04968).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI

  • Palombo, Marco
  • Navarro-Garcia, Daniel
  • Macarro, Carlos
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Grussu, Francesco
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Casanova-Salas, Irene
  • Barba, Ignasi
  • Simonetti, Sara
  • Serna, Garazi
  • Voronova, Anna
  • Corral Gámez, Juanfra
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • Mateo, Joaquin
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Liver tumour cell; In vivo diffusion MRI, Células tumorales hepáticas; Resonancia magnética de difusión in vivo, Cèl·lules tumorals hepàtiques; Ressonància magnètica de difusió in vivo, Background: Innovative diffusion Magnetic Resonance Imaging (MRI) models enable the non-invasive measurement of cancer biological properties in vivo. However, while cancers frequently spread to the liver, models tailored for liver application and easy to deploy in the clinic are still sought. We fill this gap by delivering a practical, clinically-viable framework for liver tumour diffusion imaging, informing its design through histology. Methods: We compare MRI and histological data from mice and cancer patients, namely: MRI and hemaotxylin-eosin (HE) stains from N = 7 fixed mouse livers; MRI of N = 38 patients suffering from liver solid tumours, N = 18 of whom with HE biopsies. We study five diffusion models, ranking them according to a total MRI-histology correlation score. Afterwards, we test metrics from the top-ranking model on our cohort, assessing their sensitivity to cell proliferation (Ki-67 staining, N = 10), evaluating their association with tumour volume (N = 140 tumours), and comparing them across primary cancer types. Results: We select a dMRI signal model of restricted intra-cellular diffusion with negligible extra-cellular contributions, which maximises radiological-histological correlations (total score: 0.625). The model provides cell size and density estimates that i) correlate with histology (e.g., for cell size: r = 0.44, p = 0.029), ii) are associated to Ki-67 cell proliferation (for MRI cell density: r = 0.80, p = 0.006) and tumour volume (r = 0.40, p < 10-5 for tumour volume regression), and iii) that distinguish melanoma (N = 8) from colorectal cancer (N = 13) (p = 0.011 for intra-cellular fraction). Conclusions: Our biologically meaningful approach may complement standard-of-care radiology, and become a new tool for enhanced cancer characterisation in precision oncology., We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d’Hebron University Hospital and at the Vall d’Hebron Institute of Oncology in Barcelona (Spain), without whom this study would not have been possible. We are also thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance, and to past and present members of the Radiomics group for useful discussion and advice. Finally, we would like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI21/01019” and co-funded by the European Union. Data acquisition was also supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), ISCIII (PI18/01395), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). The project that gave rise to these results received the support of a fellowship from”la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G. and A.V.) and “LCF/BQ/PI20/11760033” (funding I.C.S). I.C.S. also receives the support of the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). C.M. is funded by the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR). Funding supported personnel, data acquisition and processing, and dissemination. Funders did not influence the content of the manuscript and the decision to submit it in its current form for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

  • Castillo, Gloria
  • Martinez Perez, Paola
  • Gonzalez Medina, Alberto
  • Vila-Casadesús, Maria
  • Gómez-Rey, Marina
  • Fabregat Franco, Carles
  • TIAN, TIAN
  • Castet, Florian
  • Matito, Judit
  • Miquel Aymar, Josep Maria
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
  • Vivancos, Ana
  • SIERRA, ALEXANDRE
  • Macarulla, Teresa
Liquid biopsy; Cholangiocarcinoma; Targeted therapy, Biopsia líquida; Colangiocarcinoma; Terapia dirigida, Biòpsia líquida; Colangiocarcinoma; Teràpia dirigida, Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions in plasma and explore plasma biomarkers for managing FGFRi treatment. Experimental design: We conducted a retrospective study in 18 patients with iCCA and known FGFR2 fusions previously identified in tissue samples from prior FGFRi treatment. Both tissue and synchronous plasma samples were analyzed using a custom hybrid capture gene panel with next-generation sequencing (VHIO-iCCA panel) and validated against commercial vendor results. Longitudinal plasma analysis during FGFRi was performed. Subsequently, we explored the correlation between plasma biomarkers, liver enzymes, tumor volume, and clinical outcomes. Results: Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma. Remarkably, the analysis of plasma suggests that lower levels of ctDNA are linked to clinical benefits from targeted therapy and result in improved progression-free survival and overall survival. Higher concentrations of cell-free DNA before FGFRi treatment were linked to worse overall survival, correlating with impaired liver function and indicating compromised cell-free DNA removal by the liver. Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods. Conclusions: VHIO-iCCA demonstrated accurate detection of FGFR2 fusions in plasma. The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA., This study was supported by Incyte Corporation (Wilmington, DE; project title: “Identification of FGFR2 alterations by liquid biopsy and correlation with tissue biopsies in patients with cholangiocarcinoma”), the Asociación Española contra el Cáncer (AECC, Spain), and the FERO Foundation. A. Gonzalez-Medina is supported by the grant FJC2019-039770-I funded by Agencia Estatal de Investigación of Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033, Spain). R. Pérez-López. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19), and the Asociación Española Contra el Cáncer (AECC; PRYCO211023SERR, funding CM). A. Vivancos is supported by the Instituto de Salud Carlos III-investigación en Salud (PI20/01112). Some pictures were created with BioRender.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A framework for artificial intelligence in cancer research and precision oncology

  • Perez-Lopez, Raquel
  • Reis-Filho, Jorge S.
  • Kather, Jakob Nikolas
Artificial intelligence; Precision oncology, Intel·ligència artificial; Oncologia de precisió, Inteligencia artificial; Oncología de precisión, R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR, funding C.M.). J.N.K. is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Program of the German Cancer Aid (grant #70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union’s Horizon Europe and innovation program (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. JSR-F is funded in part by the Breast Cancer Research Foundation, a Susan G Komen Leadership grant, an NIH/NCI P50 CA247749 01 grant, and an NIH/NCI grant No. P30CA008748. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI

  • Macarro, Carlos
  • Bernatowicz, Kinga
  • García Ruiz, Alonso
  • Monreal-Agüero, Camilo
  • Corral Gámez, Juanfra
  • Merino Casabiel, Xavier
  • Mast, Richard
  • Serna, Garazi
  • Simonetti, Sara
  • Roson Gradaille, Nuria
  • Vieito , Maria
  • ESCOBAR, MANUEL
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cuantificación microestructural de tumores; Aprendizaje automático; Resonancia magnética de difusión-relajación, Quantificació microestructural del tumor; Aprenentatge automàtic; Ressonància magnètica de difusió-relaxació, Tumor microstructural quantification; Machine learning; Diffusion-relaxation magnetic resonance imaging, We thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron Campus. We would also like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO acknowledges the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe” (to R.P.L.). RPL is supported by “la Caixa” Foundation, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research has been funded by the CaixaResearch Advanced Oncology Research Program supported by “La Caixa” Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”, funding F.G. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). C.M. is supported by the Asociación Española Contra el Cancer (PRYCO211023SERR). VHIO is also grateful to the Generalitat de Catalunya, Comissió Interdepartamental de Recerca i Innovació Tecnològica.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

  • Balaguer-Montero, Maria
  • Marcos Morales, Adrià
  • Leiva, David
  • Atlagich, Luz M.
  • Staikoglou, Nikolaos
  • Monreal, Camilo
  • Hernando, Jorge
  • Garcia-Alvarez, Alejandro
  • Ligero, Marta
  • Zatse, Christina
  • Viaplana, Cristina
  • Mateo, Joaquin
  • Salvà, Francesc
  • Capdevila Castillon, Jaume
  • Dienstmann, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Elez, Elena
Deep learning; Imaging; Liver tumors, Aprendizaje profundo; Imágenes; Tumores hepáticos, Aprenentatge profund; Imatges; Tumors hepàtics, Liver tumors, whether primary or metastatic, significantly impact the outcomes of patients with cancer. Accurate identification and quantification are crucial for effective patient management, including precise diagnosis, prognosis, and therapy evaluation. We present SALSA (system for automatic liver tumor segmentation and detection), a fully automated tool for liver tumor detection and delineation. Developed on 1,598 computed tomography (CT) scans and 4,908 liver tumors, SALSA demonstrates superior accuracy in tumor identification and volume quantification, outperforming state-of-the-art models and inter-reader agreement among expert radiologists. SALSA achieves a patient-wise detection precision of 99.65%, and 81.72% at lesion level, in the external validation cohorts. Additionally, it exhibits good overlap, achieving a dice similarity coefficient (DSC) of 0.760, outperforming both state-of-the-art and the inter-radiologist assessment. SALSA’s automatic quantification of tumor volume proves to have prognostic value across various solid tumors (p = 0.028). SALSA’s robust capabilities position it as a potential medical device for automatic cancer detection, staging, and response evaluation., R.P.-L. is supported by “la Caixa” Foundation, a CRIS Cancer Foundation Talent Award (TALENT19-05), the Fero Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response

  • Navarro-Garcia, Daniel
  • Klümper, Niklas
  • Macarro, Carlos
  • Sanz, Marta
  • Alonso, Guzman
  • Lostes Bardaji, M Julia
  • Grussu, Francesco
  • Zatse, Christina
  • Hernando-Calvo, Alberto
  • Vieito , Maria
  • Brana, Irene
  • Mirallas, Oriol
  • Galvao, Vladimir
  • Pretelli, Giulia
  • Oberoi, Arjun
  • Toledo, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
Biomarcador; Inhibidor de puntos de control inmunitario; Inmunoterapia, Biomarcador; Inhibidor del punt de control immunitari; Immunoteràpia, Biomarker; Immune checkpoint inhibitor; Immunotherapy, Background The C-reactive protein (CRP) flare response, an indicator of early immune activation, has emerged as a promising and cost-effective biomarker for predicting response to immune checkpoint inhibitors (ICIs) across various tumor types. This study evaluates the utility of CRP dynamics as a tumor-agnostic biomarker and integrates systemic inflammatory markers with advanced multiparametric MRI metrics to uncover the biological mechanisms underlying the CRP flare phenomenon and its relationship with treatment response. Methods Patients were stratified into three groups based on CRP kinetics: (1) flare-responders, characterized by an initial doubling of baseline CRP followed by a decrease below baseline; (2) CRP responders, defined as patients with no flare increase but a CRP reduction of at least 30% below baseline and (3) CRP non-responders. Multiparametric MRI was performed at baseline, early (1–3 weeks), and intermediate (6–8 weeks) time points to assess tumor size and microstructural features, including cell density and vascularization. Clinical benefit and survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using Kaplan-Meier curves and log-rank tests. Cox regression analyses were performed to identify independent predictors of clinical outcomes, while intergroup differences in MRI metrics were assessed using Wilcoxon rank-sum and Kruskal-Wallis tests. Results Among the 121 evaluable patients with solid tumors enrolled in the PREDICT trial, CRP flare-responders demonstrated significantly longer PFS (5.6 months) and OS (12.1 months) compared with responders (PFS: 3.4 months, OS: 8.0 months) and non-responders (PFS: 3.2 months, OS: 6.7 months; p=0.01 and p<0.01, respectively). Additionally, clinical benefit was achieved in 50% of flare-responders, compared with 13% of responders (p=0.05) and 23% of non-responders (p<0.01). Tumor growth was interrupted early after treatment initiation in CRP flare-responders, whereas non-responders exhibited marked increases in tumor size. In the pilot subset of 33 patients with MRI data, diffusion MRI revealed stable or increased apparent diffusion coefficient values in CRP flare-responders, indicative of reduced tumor cellularity just after 1–3 weeks of treatment. Conclusions This study highlights the potential of combining early CRP dynamics with non-invasive imaging metrics to identify ICI responders as early as 2 weeks after treatment initiation. By integrating systemic inflammatory biomarkers with MRI-derived insights into tumor size and microstructural changes, these findings optimize therapeutic strategies and advance understanding of immunotherapy-driven tumor dynamics., This research has been supported by PREDICT sponsored by AstraZeneca. RP-L is also supported by a CRIS Foundation Talent Award (TALENT19-05), Asociacion Espanola Contra el Cancer (AECC) (PRYCO211023SERR), the FERO Foundation, “la Caixa” Foundation, Instituto de Salud Carlos III-Investigación en Salud (PI21/01019), and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). FG receives the support of a fellowship from "la Caixa" Foundation (ID 100010434). The fellowship code is "LCF/BQ/PR22/11920010". Vall d’Hebron Institut d’Oncologia (VHIO) authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Centre of Excellence Severo Ochoa (CEX2020-001024-S/AEI/ 10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the Generalitat de Catalunya CERCA Programme for their support of this research. We would like to acknowledge all the patients who participated in this and other clinical research projects for their contribution to science. AHC would like to acknowledge Contrato Rio Hortega 2024 and Beca Gilead a la Investigación Biomedica.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?

  • Gielen, Bente
  • Prior, Olivia
  • Ligero, Marta
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Cresta Morgado, Pablo
  • Navarro Garces, Victor
Biomarkers; Immunotherapy; Cancer, Biomarcadors; Immunoteràpia; Càncer, Biomarcadores; Inmunoterapia; Cáncer, The search for understanding immunotherapy response has sparked interest in diverse areas of oncology, with artificial intelligence (AI) and radiomics emerging as promising tools, capable of gathering large amounts of information to identify suitable patients for treatment. The application of AI in radiology has grown, driven by the hypothesis that radiology images capture tumor phenotypes and thus could provide valuable insights into immunotherapy response likelihood. However, despite the rapid growth of studies, no algorithms in the field have reached clinical implementation, mainly due to the lack of standardized methods, hampering study comparisons and reproducibility across different datasets. In this review, we performed a comprehensive assessment of published data to identify sources of variability in radiomics study design that hinder the comparison of the different model performance and, therefore, clinical implementation. Subsequently, we conducted a use-case meta-analysis using homogenous studies to assess the overall performance of radiomics in estimating programmed death-ligand 1 (PD-L1) expression. Our findings indicate that, despite numerous attempts to predict immunotherapy response, only a limited number of studies share comparable methodologies and report sufficient data about cohorts and methods to be suitable for meta-analysis. Nevertheless, although only a few studies meet these criteria, their promising results underscore the importance of ongoing standardization and benchmarking efforts. This review highlights the importance of uniformity in study design and reporting. Such standardization is crucial to enable meaningful comparisons and demonstrate the validity of biomarkers across diverse populations, facilitating their implementation into the immunotherapy patient selection process., This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021). RPL is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019), the Prostate Cancer Foundation (18YOUN19) and the Asociacion Española Contra el Cancer (AECC) (PRYCO211023SERR). ML is supported by the PERIS PIF-Salut Grant. OP is supported by a La Caixa INPhINIT Fellowship.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

High-dimensional mass cytometry identified circulating natural killer T-cell subsets associated with protection from cytomegalovirus infection in kidney transplant recipients

  • JOUVE, Thomas
  • Bin, Sofia
  • Hartzell, Susan
  • Torija Recasens, Alba
  • Jarque, Marta
  • KERVELLA, Delphine
  • Zuñiga-Vergara, Jose-Miguel
  • Font-Miñarro, Cristina
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Perelló, Manel
  • Donadeu Casassas, Laura
  • Martínez Gallo, Mónica
  • Meneghini, Maria
  • TOAPANTA, NÉSTOR
  • Moreso, Francesc
  • Bestard, Oriol
  • Crespo, Elena
Cytomegalovirus; Kidney transplantation; Mass spectrometry, Citomegalovirus; Trasplante de riñón; Espectrometría de masas, Citomegalovirus; Trasplantament de ronyó; Espectrometria de masses, Cytomegalovirus (CMV) infection is associated with poor kidney transplant outcomes. While innate and adaptive immune cells have been implicated in its prevention, an in-depth characterization of the in vivo kinetics of multiple cell subsets and their role in protecting against CMV infection has not been achieved. Here, we performed high-dimensional immune phenotyping by mass cytometry, and functional assays, on 112 serially collected samples from CMV seropositive kidney transplant recipients. Advanced unsupervised deep learning analysis was used to assess immune cell populations that significantly correlated with prevention against CMV infection and anti-viral immune function. Prior to infection, kidney transplant recipients who developed CMV infection showed significantly lower CMV-specific cell-mediated immune (CMI) frequencies than those that did not. A broad diversity of circulating cell subsets within innate and adaptive immune compartments were associated with CMV infection or protective CMV-specific CMI. While percentages of CMV (tetramer-stained)-specific T cells associated with high CMI responses and clinical protection, circulating CD3+CD8midCD56+ NK-T cells overall strongly associated with low CMI and subsequent infection. However, three NK-T cell subsets sharing the CD11b surface marker associated with CMV protection and correlated with strong anti-viral CMI frequencies in vitro. These data were validated in two external independent cohorts of kidney transplant recipients. Thus, we newly describe the kinetics of a novel NK-T cell subset that may have a protective role in post-transplantation CMV infection. Our findings pave the way to more mechanistic studies aimed at understanding the function of these cells in protection against CMV infection., LD received a research fellowship grant from the “Instituto de Salud Carlos III” (FI22/00252). TJ received a fellowship grant from the European Society of Organ Transplantation (2020 fellowship grant). PC is acting as a consultant for Chinook Therapeutics and has received research funding from Chinook Therapeutics. OB’s research activity is partly supported by Instituto de Salud Carlos III (grant numbers PI19/01710 and PI22/01019; cofunded by the European Regional Development Fund, a way to build Europe) and redes de Investigación Cooperativa Orientadas a Resultados en Salud consortia by the Instituto de Salud Carlos III. Also, the work was partially funded by a European Union Horizon 2020 research and innovation program under grant agreement 754995 (EUTRAIN).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

  • Novikov, Dmitry
  • Grigoriou, Athanasios
  • Bernatowicz, Kinga
  • Simonetti, Sara
  • Serna, Garazi
  • Roson Gradaille, Nuria
  • ESCOBAR, MANUEL
  • Vieito , Maria
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • Grussu, Francesco
Cancer; Capillary flow; Diffusion MRI, Cáncer; Flujo capilar; Resonancia magnética de difusión, Càncer; Flux capil·lar; Ressonància magnètica de difusió, Diffusion Magnetic Resonance Imaging (dMRI) sensitises the MRI signal to spin motion. This includes Brownian diffusion, but also flow across intricate networks of capillaries. This effect, the intra-voxel incoherent motion (IVIM), enables microvasculature characterisation with dMRI, through metrics such as the vascular signal fraction or the vascular Apparent Diffusion Coefficient (ADC) . The IVIM metrics, while sensitive to perfusion, are protocol-dependent, and their interpretation can change depending on the flow regime spins experience during the dMRI measurements (e.g., diffusive vs ballistic), which is in general not known for a given voxel. These facts hamper their practical clinical utility, and innovative vascular dMRI models are needed to enable the in vivo calculation of biologically meaningful markers of capillary flow. These could have relevant applications in cancer, as in the assessment of the response to anti-angiogenic therapies targeting tumour vessels. This paper tackles this need by introducing SpinFlowSim, an open-source simulator of dMRI signals arising from blood flow within pipe networks. SpinFlowSim, tailored for the laminar flow patterns within capillaries, enables the synthesis of highly-realistic microvascular dMRI signals, given networks reconstructed from histology. We showcase the simulator by generating synthetic signals for 15 networks, reconstructed from liver biopsies, and containing cancerous and non-cancerous tissue. Signals exhibit complex, non-mono-exponential behaviours, consistent with in vivo signal patterns, and pointing towards the co-existence of different flow regimes within the same network, as well as diffusion time dependence. We also demonstrate the potential utility of SpinFlowSim by devising a strategy for microvascular property mapping informed by the synthetic signals, and focussing on the quantification of blood velocity distribution moments and of an apparent network branching index. These were estimated in silico and in vivo, in healthy volunteers scanned at 1.5T and 3T and in 13 cancer patients, scanned at 1.5T. In conclusion, realistic flow simulations, as those enabled by SpinFlowSim, may play a key role in the development of the next-generation of dMRI methods for microvascular mapping, with immediate applications in oncology., VHIO would like to acknowledge: the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support on this research. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund ‘A way to make Europe’ (to R.P.L.), and by the Comprehensive Program of Cancer Immunotherapy and Immunology (CAIMI), funded by the Banco Bilbao Vizcaya Argentaria Foundation Foundation (FBBVA, grant 89/2017). R.P.L. is supported by the “la Caixa” Foundation CaixaResearch Advanced Oncology Research Program, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05, the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Generalitat de Catalunya Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178, SGR-Cat2021). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010” (funding F.G., A.V., and A.G.). This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). M.P. is supported by the UKRI Future Leaders Fellowship MR/T020296/2. A.G. is supported by a Severo Ochoa PhD fellowship (PRE2022-102586). The authors are thankful to the Vall d’Hebron Radiology department and to the ASCIRES CETIR clinical team for their assistance with MRI acquisitions, and to the GE/Siemens clinical scientists for their support with diffusion sequence characterisation. We are also thankful to patients and their families, and to Prof Roser Sala-Llonch from the University of Barcelona for useful discussion and institutional support.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study

  • Ramlee, Syafiq
  • Hulse, David
  • Pérez López, Raquel
  • Sala, Evis
  • Aloj, Luigi
  • Bernatowicz, Kinga
Cancer; Immune cells; Lymphocytes, Cáncer; Células inmunes; Linfocitos, Càncer; Cèl·lules immunitàries; Limfòcits, The tumour immune microenvironment influences the efficacy of immune checkpoint inhibitors. Within this microenvironment are CD8-expressing tumour-infiltrating lymphocytes (CD8+ TILs), which are an important mediator and marker of anti-tumour response. In practice, the assessment of CD8+ TILs via tissue sampling involves logistical challenges. Radiomics, the high-throughput extraction of features from medical images, may offer a novel and non-invasive alternative. We performed a systematic review of the available literature reporting radiomic signatures associated with CD8+ TILs. We also aimed to evaluate the methodological quality of the identified studies using the Radiomics Quality Score (RQS) tool, and the risk of bias and applicability with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. Articles were searched from inception until 31 December 2021, in three electronic databases, and screened against eligibility criteria. Twenty-seven articles were included. A wide variety of cancers have been studied. The reported radiomic signatures were heterogeneous, with very limited reproducibility between studies of the same cancer group. The overall quality of studies was found to be less than desirable (mean RQS = 33.3%), indicating a need for technical maturation. Some potential avenues for further investigation are also discussed., This work was supported by the Cancer Research UK (CRUK) Cambridge Centre (CTRQQR-2021\100012) and the CRUK National Cancer Imaging Translational Accelerator (NCITA) (C22479/A28667); additional support was also provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014); the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care; S.R. is supported by the Brunei “Sultan’s Scholar” scholarship from the Sultan Haji Hassanal Bolkiah Foundation; D.H. is supported by the Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies project (RG96994 and 831514); K.B. is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182); R.P.L. is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

  • Ros Montañá, Fco. Javier
  • Fernández, Jose
  • Moreno-Cárdenas, Ana Belén
  • Arenillas Lallana, Carlota
  • Fasani, Roberta
  • Garcia Rodriguez, Ariadna
  • Gonzalo-Ruiz, Javier
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Pérez López, Raquel
  • Tabernero, Josep
  • De Almeida Toledo, Rodrigo
  • Comas Navarro, Raquel
  • Dienstmann, Rodrigo
  • Bernatowicz, Kinga
  • Piris-Giménez, Alejandro
  • Elez Fernandez, Mª Elena
  • Villacampa Javierre, Guillermo
Colorectal cancer; Predictive markers; Tumour biomarkers, Cáncer colorrectal; Marcadores predictivos; Biomarcadores tumorales, Càncer colorrectal; Marcadors predictius; Biomarcadors tumorals, Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRCBRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients., VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigación) (CEX2020-001024-S / AEI / 10.13039 /501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundación AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

  • Ligero, Marta
  • El Nahhas, Omar
  • SANSANO, IRENE
  • Mauchanski, Siarhei
  • Serna, Garazi
  • Viaplana, Cristina
  • Toledo, Rodrigo
  • Dienstmann, Rodrigo
  • Ramon y Cajal, Santiago
  • GARRALDA, Elena
  • Nuciforo, Paolo
  • Perez-Lopez, Raquel
Deep learning; Immunotherapy; Solid tumors, Aprenentatge profund; Immunoteràpia; Tumors sòlids, Aprendizaje profundo; Inmunoterapia; Tumores sólidos, Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1–stained slides from the non–small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1–2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96–2.2), P = 0.082] and CPS [HR: 1.2 (0.79–1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity. Significance: The weakly supervised DL model to predict PD-L1 status from raw IHC data, integrating tumor staining intensity and morphology, enables enhanced patient stratification in cancer immunotherapy compared with traditional pathologist assessment., J.N. Kather is supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Max-Eder-Programme of the German Cancer Aid (grant no. 70113864), the German Federal Ministry of Education and Research (PEARL, 01KD2104C; CAMINO, 01EO2101; SWAG, 01KD2215A; TRANSFORM LIVER, 031L0312A; TANGERINE, 01KT2302 through ERA-NET Transcan), the German Academic Exchange Service (SECAI, 57616814), the German Federal Joint Committee (Transplant.KI, 01VSF21048) the European Union's Horizon Europe and innovation programme (ODELIA, 101057091; GENIAL, 101096312) and the National Institute for Health and Care Research (NIHR, NIHR213331) Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. R. Perez-Lopez is supported by LaCaixa Foundation, a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). M. Ligero is supported by the PERIS PIF-Salut Grant. As per the ICMJE guidelines of April 2023, we hereby disclose that the following artificial intelligence tools were used to write this article: ChatGPT-4 for checking and correcting spelling and grammar.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

  • Zacchi, Francesca
  • Semidey Raven, Maria Eugenia
  • Maldonado, Xavier
  • Perez-Lopez, Raquel
  • Mateo, Joaquin
  • Macarena, Gonzalez
  • Carles, Joan
Bone metastases; Bone response; Metastatic castration-resistant prostate cancer, Metástasis óseas; Respuesta ósea; Cáncer de próstata resistente a la castración metastásico, Metàstasis òssies; Resposta òssia; Càncer de pròstata resistent a la castració metastàtic, Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients' outcomes are heterogenous, and there is lack of validated predictive biomarkers of response, while biomarkers for early identification of patients who benefit from treatment are limited. This case report describes a remarkable and durable response to Ra-223 in a CRPC patient with bone metastases who had rapidly progressed to many previous therapies; this response is now lasting for 5 years even after having stopped backbone androgen deprivation therapy (ADT). Here, we present the clinical course of this exceptional response, as well as comprehensive genomic and histopathology analyses on sequential biopsies acquired before and after therapy. Additionally, we review current knowledge on predictive and response biomarkers to Ra-223 in metastatic prostate cancer., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge funding from CRIS Cancer Foundation (grant TCL_2020-10 to JM) and Fundación AECC (LABAE20019MATE to JM) and FERO Foundation. RP-L is supported by LaCaixa Foundation, a CRIS Foundation Talent Award TALENT19-05, the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud PI18/01395 and PI21/01019 and the Prostate Cancer Foundation 18YOUN19.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

  • Zatse, Christina
  • Garazi, Serna
  • Bernatowicz, Kinga
  • Amat Ferrer, Ramon
  • Prior, Olivia
  • Frigola Rissech, Joan
  • Ligero, Marta
  • Grussu, Francesco
  • Nuciforo, Paolo
  • Toledo, Rodrigo
  • ESCOBAR, MANUEL
  • GARRALDA, Elena
  • Perez-Lopez, Raquel
  • FELIP, ENRIQUETA
Computed tomography; Immunotherapy; Tumor microenvironment, Tomografía computarizada; Inmunoterapia; Microambiente tumoral, Tomografia computeritzada; Immunoteràpia; Microambient tumoral, Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies have triggered the exploration of non-invasive alternatives, such as radiomics, to comprehensively evaluate TIME across diverse cancers. To address these challenges, we develop an ICI response signature by integrating radiomics with T cell-inflamed gene-expression profiles. Methods: We conducted a pan-cancer investigation into the utility of radiomics for TIME assessment, including 1360 tumors from 428 patients. Leveraging contrast-enhanced CT images, we characterized TIME through RNA gene expression analysis, using the T cell-inflamed gene expression signature. Subsequently, a pan-cancer CT-radiomic signature predicting inflamed TIME (CT-TIME) was developed and externally validated. Machine learning was employed to select robust radiomic features and predict inflamed TIME. The study also integrated independent cohorts with longitudinal CT images, baseline biopsies, and comprehensive immunohistochemistry panel evaluation to assess the pan-cancer biological associations, spatiotemporal landscape and clinical utility of the CT-TIME. Results: The CT-TIME signature, comprising four radiomic features linked to a T-cell inflamed microenvironment, demonstrated robust performance with AUCs (95% CI) of 0.85 (0.73 to 0.96) (training) and 0.78 (0.65 to 0.92) (external validation). CT-TIME scores exhibited positive correlations with CD3, CD8, and CD163 expression. Intrapatient analysis revealed considerable heterogeneity in TIME between tumors, which could not be assessed using biopsies. Evaluation of aggregated per-patient CT-TIME scores highlighted its promising clinical utility for dynamically assessing the immune microenvironment and predicting immunotherapy response across diverse scenarios in advanced cancer. Despite demonstrating progression disease at the first follow-up, patients within the inflamed status group, identified by CT-TIME, exhibited significantly prolonged progression-free survival (PFS), with some surpassing 5 months, suggesting a potential phenomenon of pseudoprogression. Cox models using aggregated CT-TIME scores from baseline images revealed a statistically significant reduction in the risk of PFS in the pan-cancer cohort (HR 0.62, 95% CI 0.44 to 0.88, p=0.007), and Kaplan-Meier analysis further confirmed substantial differences in PFS between patients with inflamed and uninflamed status (log-rank test p=0.009). Conclusions: The signature holds promise for impacting clinical decision-making, pan-cancer patient stratification, and treatment outcomes in immune checkpoint therapies., KB is supported by MSCA COFUND Beatriu de Pinós Grant (2019BP/00182). FG receives the support of a fellowship from LaCaixa Foundation (ID 100010434). The fellowship code is LCF/BQ/PR22/11920010. RP-L is supported by CRIS Cancer Foundation (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019) and the Prostate Cancer Foundation (18YOUN19). OP was funded by Fundació “LaCaixa” (ID 100010434, code LCF/BQ/DR21/11880027).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

An accessible deep learning tool for voxel-wise classification of brain malignancies from perfusion MRI

  • Garcia Ruiz, Alonso
  • Pons-Escoda, Albert
  • Naval-Baudin, Pablo
  • Monreal-Aguero, Camilo
  • Hermann, Gretchen
  • Grussu, Francesco
  • Ligero, Marta
  • Perez-Lopez, Raquel
Deep learning; Glioblastoma; Perfusion MRI, Aprenentatge profund; Glioblastoma; Ressonància magnètica de perfusió, Aprendizaje profundo; Glioblastoma; Resonancia magnética de perfusión, Noninvasive differential diagnosis of brain tumors is currently based on the assessment of magnetic resonance imaging (MRI) coupled with dynamic susceptibility contrast (DSC). However, a definitive diagnosis often requires neurosurgical interventions that compromise patients' quality of life. We apply deep learning on DSC images from histology-confirmed patients with glioblastoma, metastasis, or lymphoma. The convolutional neural network trained on ∼50,000 voxels from 40 patients provides intratumor probability maps that yield clinical-grade diagnosis. Performance is tested in 400 additional cases and an external validation cohort of 128 patients. The tool reaches a three-way accuracy of 0.78, superior to the conventional MRI metrics cerebral blood volume (0.55) and percentage of signal recovery (0.59), showing high value as a support diagnostic tool. Our open-access software, Diagnosis In Susceptibility Contrast Enhancing Regions for Neuro-oncology (DISCERN), demonstrates its potential in aiding medical decisions for brain tumor diagnosis using standard-of-care MRI., This project was supported by “La Caixa” Foundation (RTI2018-095209-B-C21) and the Spanish Ministry of Science and Innovation (FIS-G64384969). R.P.-L. is supported by the Prostate Cancer Foundation Young Investigator Award, the FERO Foundation, the CRIS Foundation Talent Award (TALENT19-05), the Instituto de Salud Carlos III Investigacion en Salud (PI21/01019), and the Asociacion Espanola Contra el Cancer (PRYCO211023SERR). F.G. was funded by the Government of Catalonia (Beatriu de Pinos 2020 00117 BP) and by the Fundacio LaCaixa (ID 100010434, code LCF/BQ/PR22/11920010). C.M. and A.P.-E. acknowledge support from the Instituto de Salud Carlos III-Investigación en Salud (PI20/00360). We would like to express our sincere appreciation to Javier Carmona for his valuable support and assistance in reviewing the manuscript.